The Bidirectional Relationship Between Mental Health Disorders and Hepatitis C Virus (Hcv) Among Drug Users

The Bidirectional Relationship Between Mental Health Disorders and Hepatitis C Virus (Hcv) Among Drug Users | Research Square window.SnipcartSettings = { analytics: { enabled: false } }; (function() { var accessVector = localStorage.getItem('access_vector') || ''; window.dataLayer = window.dataLayer || []; if (accessVector) { window.dataLayer.push({ user: { profile: { profileInfo: { snid: accessVector } } } }); } })(); (function(w,d,s,l,i){w[l]=w[l]||[];w[l].push({'gtm.start':new Date().getTime(),event:'gtm.js'});var f=d.getElementsByTagName(s)[0],j=d.createElement(s),dl=l!='dataLayer'?'&l='+l:'';j.async=true;j.src='https://www.googletagmanager.com/gtm.js?id='+i+dl;f.parentNode.insertBefore(j,f);})(window,document,'script','dataLayer','GTM-K279D39R'); Browse Preprints In Review Journals COVID-19 Preprints AJE Video Bytes Research Tools Research Promotion AJE Professional Editing AJE Rubriq About Preprint Platform In Review Editorial Policies Our Team Advisory Board Help Center Sign In Submit a Preprint Cite Share Download PDF Systematic Review The Bidirectional Relationship Between Mental Health Disorders and Hepatitis C Virus (Hcv) Among Drug Users Perseverance N Moyo, David S.O Abafi, Becky Masele, Wuraola R. Awosan, and 1 more This is a preprint; it has not been peer reviewed by a journal. https://doi.org/ 10.21203/rs.3.rs-8702097/v1 This work is licensed under a CC BY 4.0 License Status: Posted Version 1 posted You are reading this latest preprint version Abstract Background People Who Use Drugs (PWUD) are disproportionately affected by both Mental Health Disorders (MHD) and Hepatitis C Virus (HCV). Research indicates that individuals with Serious Mental Illness (SMI) have an HCV prevalence of approximately 8%, while nearly 40% of drug users report conditions such as depression, anxiety, and bipolar disorder. There is a dearth of knowledge on the intersection of HCV, MHD, and substance abuse. Methods This narrative literature review synthesizes findings from peer-reviewed research examining the bidirectional relationship between mental health disorders and HCV among PWUD. Studies were identified using targeted keyword searches across multiple databases, focusing on co-occurrence, prevalence, treatment outcomes, and risk factors. Results Mental health conditions contribute to increased HCV risk by promoting risky behaviors such as needle sharing and reduced adherence to HCV treatment. Conversely, HCV negatively affects mental health via biological mechanisms like neuroinflammation and the psychological burden of chronic illness. Integrated treatment models addressing both mental health and HCV show improved adherence and outcomes, though evidence remains limited. Conclusions There is an urgent need for integrated, interdisciplinary approaches to treatment that address both mental health disorders and HCV among drug users. Future research should prioritize longitudinal studies, focus on underrepresented populations, and evaluate the effectiveness of integrated care models. Hepatitis C mental health disorders drug use co-occurring disorders integrated care public health Figures Figure 1 1.0 INTRODUCTION Over 3,500 people die every day from hepatitis C virus (HCV) infection, and there are approximately 1 million new cases of hepatitis B and C combined reported worldwide each year, highlighting the seriousness of this disease as a major global health concern (World Health Organization [WHO], 2025; Centers for Disease Control and Prevention [CDC], 2024). HCV is a major cause of liver-related disease and mortality, such as cirrhosis and hepatocellular carcinoma, and it presently affects an estimated 50 million individuals globally. HCV is a major cause of liver-related disease and mortality, such as cirrhosis and hepatocellular carcinoma, and it presently affects an estimated 50 million individuals globally, representing a substantial global disease burden across regions including the United States and other heavily affected countries (Yang et al., 2023). The development of effective antiviral treatments has advanced significantly, most notably with the introduction of direct-acting antivirals (DAAs), which have fewer side effects and high cure rates than earlier treatments. Nevertheless, there are still significant gaps in diagnosis, treatment access, and care engagement. (CDC, 2024). For example, less than 20% of those living with HCV have received curative treatment with DAAs, and less than 40% of them are aware of their infection status worldwide (CDC, 2024). Among high-risk groups, such as drug users (PWUD), where stigma, concurrent mental health disorders, structural hurdles, and poor access to healthcare make vulnerability worse these disparities are particularly noticeable. Mental health and substance use disorders are increasingly recognized as major global public health priorities due to their high prevalence, substantial treatment gaps, and close interaction with other chronic diseases, particularly among vulnerable populations such as people who use drugs (Baingana et al., 2015 ). The high incidence and disproportionate health impact of HCV in these regions this population underscores the pressing need for integrated care models and focused public health initiatives to enhance screening, care linkage, and treatment results (CDC, 2024). Hepatitis C virus (HCV) infection, mental illness, and substance usage combine to create a complicated and mutually reinforcing triple threat that has significant effects on both public and individual health outcomes. Hepatitis C virus (HCV) infection, mental illness, and substance use frequently co-occur among people who use drugs and together contribute to elevated risk behaviors, reduced access to care, and poorer treatment outcomes. The prevalence of HCV among people who inject drugs (PWID) is still astonishingly high, frequently surpassing 50% in several environments. High-risk practices that promote effective viral transmission, such as sharing syringes, needles, and other contaminated injection supplies, are mostly to blame for this increased rate (Hashim et al., 2021 ). However, infectious diseases are not the only health problems this population faces. Mental health conditions like depression, anxiety, PTSD, and psychotic disorders are very common among drug users and these co-occurring psychiatric conditions not only make substance use behaviors worse but also pose major obstacles to accessing healthcare services like HCV screening, diagnosis, and treatment adherence.( Connery et al. ( 2020 ) also note that approximately 40% of people who use drugs (PWUD) fulfill the diagnostic criteria for at least one mental health issue, and nearly half of people with serious mental illness (SMI) also use drugs problematically. Aside from making treatment more difficult, this co-morbidity increases the burden of disease and emphasizes the necessity of integrated, multidisciplinary methods to care that concurrently address infectious disease and mental health. It is becoming well acknowledged that there is a bidirectional association between hepatitis C virus (HCV) infection and mental health disorders, with important ramifications for long-term results, prevention, and treatment. Those with mental health conditions are more likely to contract HCV, especially those that involve emotional dysregulation, a history of trauma, cognitive deficits, or impulsiveness. These vulnerabilities frequently manifest as increased substance use, high-risk injection behaviors, and noncompliance with treatment or prevention plans (Mahoney et al., 2024 ; Khan et al., 2024). Particularly among people who inject drugs (PWID), concomitant mental illnesses including depression, anxiety, or post-traumatic stress disorder (PTSD) might affect judgment and self-care practices, making it more likely that they will be exposed to HCV in high-risk settings (Khan et al., 2024). Conversely, there are several ways in which persistent HCV infection can either cause or exacerbate mental health issues. Biologically, HCV can cause hepatic encephalopathy, immunological dysregulation, and neuroinflammation; these conditions have all been linked to fluctuations in mood, exhaustion, and cognitive impairment (Guo et al., 2023 ; Ahmed et al., 2023 ). Psychosocially, having chronic, stigmatized illness can cause psychological anguish, low self-esteem, and social isolation. Furthermore, new research indicates that HCV may have direct neurotropic effects, affecting the functioning of the central nervous system even when there is no advanced liver disease. This could lead to cognitive decline, depression symptoms, and a lower quality of life (Faccioli et al., 2021 ). The combination of substance use, mental health issues, and hepatitis C virus (HCV) greatly increases the chance of reinfection and worsens morbidity, in addition to making diagnosis and treatment more difficult. This increases the likelihood that patients would stop using healthcare services, interrupt treatment courses, and not take their medications as directed. This increases the likelihood that patients will disengage from healthcare services, experience interruptions in treatment courses, and demonstrate poor medication adherence. This compromises not only clinical results but also the advancement of public health objectives, such the WHO's HCV eradication ambitions. The consequences are not just clinical but also financial, placing a significant strain on healthcare systems around the world (Sulkowski et al. 2020 ). Based on the severity of the disease, annual healthcare costs for people with chronic HCV can vary greatly, from about $ 10,561 for those without cirrhosis to over $ 46,000 for those with advanced liver disease, such as cirrhosis or hepatocellular carcinoma (Sulkowski et al., 2020 ). These expenses cover hospital stays, diagnostic procedures, antiviral therapy, outpatient visits, and the handling of problems. These expenses are frequently overshadowed by the high upfront costs of direct-acting antivirals (DAAs) and the systemic difficulties in enrolling and keeping underserved populations in care, even though the introduction of DAAs has greatly increased cure rates and decreased long-term costs, resulting in savings of about $ 15,900 per patient annually following successful treatment (Marcellusi et al., 2022 ). To tackle this complex problem, we must move toward integrated, multidisciplinary care approaches that take the social, psychological, and medical requirements of PWUD into account. Separate treatments Siloed care approaches are insufficient in this population since mental health conditions and HCV are syndetic. To improve health equity and meet eradication targets, holistic approaches that combine harm reduction, addiction treatment, mental health services, and HCV screening and therapy are crucial. The purpose of this review is to compile the most recent research on the reciprocal association between drug use and mental health conditions and HCV. It assesses treatment results in integrated care settings, investigates the ways in which different illnesses interact, and pinpoints knowledge and practice gaps. We want to influence therapeutic interventions, public health policy, and future research paths in line with the worldwide HCV elimination goals by clarifying the interdependencies between viral infections and mental health in this vulnerable population. 2.0 METHODS 2.1 Design This study employed a narrative literature review approach to examine the bidirectional relationship between mental health disorders and hepatitis C virus (HCV) infection among people who use drugs (PWUD). The review aimed to identify, summarize, and interpret existing peer-reviewed evidence on prevalence, risk behaviors, treatment adherence, integrated care models, and psychosocial factors influencing both conditions. 2.2 Search Strategy A structured literature search was conducted across PubMed, PsycINFO, Scopus, and Google Scholar to examine the relationships between mental health disorders, substance use, and hepatitis C virus (HCV) among people who use drugs (PWUD). Key search combinations included “mental health and hepatitis C,” “mental health disorders and substance use,” “substance use and hepatitis C,” and “co-occurring disorders.” Initial searches yielded approximately 16,200, 16,700, 17,800, and 915 articles, respectively, prior to screening as seen in Fig. 1 . 2.3 Inclusion and Exclusion Criteria To be included in the review, studies had to meet the following criteria: Published in English between 2010 and 2025. Peer-reviewed articles examining mental health and HCV in the context of drug use. Focus on adult populations (18 + years). Include quantitative, qualitative, or mixed methods designs. Exclusion criteria included: Studies focusing exclusively on non-drug-using populations. Editorials, commentaries, or studies lacking empirical data. 2.4 Selection and Data Extraction In order to determine relevance, two researchers independently assessed the first search results by title and abstract. All publications that satisfied the first inclusion criteria were then evaluated in full by both reviewers. A third reviewer was on hand to offer arbitration in the event of a disagreement; however, no contradictory evaluations emerged during the screening process, and all choices were agreed upon. A standardized template was used for data extraction in order to methodically record data on research type, sample characteristics, treatment outcomes, documented impediments to integrated care, and the prevalence of HCV and mental health. A thematic synthesis was conducted after extraction in order to identify important gaps in the body of current research, summarize findings, and extract key trends. 2.5 Ethical Considerations As this review utilized publicly available data from previously published studies, no ethical approval was required. 3.0 RESULTS An initial pool of 51,615 papers was found through a methodical examination of electronic databases (PubMed, PsycINFO, Scopus, Google Scholar) using specific keywords relating to substance use, mental health, and hepatitis C. 127 articles were kept for full-text review after titles and abstracts were screened for relevancy. 39 studies were found to be qualified for inclusion in this narrative review after the inclusion and exclusion criteria (such as English language, publication between 2010 and 2025, and emphasis on adult PWUD) were applied. Table 1 shows a summary of the findings of papers in this narrative review. The findings from the reviewed literature reveal a strong bidirectional association between mental health disorders and hepatitis C virus (HCV) infection among people who use drugs (PWUD). Three central themes emerged: (1) the impact of mental health conditions on HCV risk behaviors and treatment adherence, (2) the effects of chronic HCV infection on psychological well-being, and (3) the outcomes of integrated treatment approaches for co-occurring conditions. 3.1 Mental Health Disorders and Increased Risk of HCV Numerous studies have reported that individuals with mental health disorders, particularly depression, anxiety, bipolar disorder, and post-traumatic stress disorder (PTSD), are at significantly higher risk for engaging in behaviors that facilitate HCV transmission. These behaviors include sharing needles, cookers, and inhalation paraphernalia (Connery et al., 2020; Mahoney et al., 2024). Among individuals with serious mental illness (SMI), HCV prevalence was found to be approximately 8%, with rates up to 11 times higher than in the general population (Braude et al., 2021). Mental health conditions were also linked to poor engagement in harm reduction programs and inconsistent use of sterile equipment. Roncero et al. (2023) emphasized the prevalence of HCV infection in patients with chronic mental disorders, noting that dual disorders (co-occurring substance use and mental health issues) significantly exacerbate the risk. Their findings highlight the importance of addressing both mental health and substance use in treatment settings to reduce HCV transmission rates effectively. Specifically, the study found that patients with both mental health disorders and substance use issues exhibited higher rates of risky behaviors, such as sharing syringes and other paraphernalia, which directly contribute to the spread of HCV. In a rural New Mexico cohort, Gupta et al. (2022) identified a strong association between co-occurring mental health problems and HCV status among young people who inject drugs (PWID). Their research indicated that PTSD had a significant impact on HCV infection rates, mediated by risky injection behaviors such as receptive syringe sharing (RSS). This underscores the need for targeted interventions that integrate mental health services into harm reduction strategies. The study also highlighted that young PWID with a history of trauma were more likely to engage in risky injection practices, amplifying their vulnerability to HCV infection. Aas et al. (2024) further explored the effects of integrated HCV treatment on psychological distress in people with substance use disorders. Their study found that improving access to mental health care and reducing psychological distress could potentially mitigate the risk of HCV transmission among vulnerable populations. The integration of mental health services into HCV treatment not only addresses the psychological needs of patients but also encourages better adherence to treatment protocols and harm reduction practices. 3.2 The effects of chronic HCV infection on psychological well-being HCV infection can adversely impact mental health through both biological and psychological mechanisms. Chronic infection has been associated with neuroinflammatory processes that contribute significantly to the development of depressive and anxiety symptoms, highlighting the complex interplay between physical and mental health (Guo et al., 2023). Chronic viral hepatitis, including HCV, is associated with a range of neuropsychiatric manifestations such as depression, anxiety, cognitive impairment, and fatigue, driven by neuroinflammatory and metabolic mechanisms (Polukchi et al., 2023). The stress of living with a stigmatized, incurable illness often results in social isolation, hopelessness, and worsening psychiatric conditions, with these effects being particularly pronounced among individuals who already struggle with pre-existing mental health disorders or lack stable social support systems (Ahmed et al., 2023; NIMH, 2025). Research shows that HCV leads to neuroinflammation, disrupting neurotransmitter systems crucial for mood regulation. This disruption can exacerbate existing mood disorders, such as depression and anxiety, thus creating a cycle of worsening health (Okobi et al., 2024). Moreover, the psychological burden associated with HCV can amplify feelings of shame and social isolation, leading to a reluctance to seek necessary medical help or engage in supportive communities. Stigmatization surrounding HCV often deters individuals from pursuing treatment, which can further exacerbate their mental health challenges (Flisiak et al., 2025). In addition to these psychological impacts, the presence of mental health disorders complicates adherence to HCV treatment regimens. Individuals facing co-occurring conditions often experience barriers such as cognitive impairment, emotional distress, and a lack of motivation, all of which hinder their ability to comply with treatment protocols effectively (Taye, 2021). The cumulative effect of these challenges underscores the urgent need for integrated care models that address both HCV and mental health simultaneously. Such models can facilitate better health outcomes by ensuring that individuals receive comprehensive care tailored to their unique needs. 3.3 Outcomes of integrated treatment approaches for co-occurring conditions. Evidence from integrated care models suggests that addressing mental health and HCV concurrently leads to improved treatment adherence, higher sustained virologic response, and improved mental health outcomes (Mahoney et al., 2024).Studies highlighted those patients receiving coordinated care where psychiatric support is embedded within HCV treatment programs demonstrated better medication adherence, higher rates of sustained virologic response (SVR), and improved mental health outcomes (Mahoney et al., 2024). However, many of these models remain underutilized due to structural barriers, provider shortages, and stigma associated with both conditions. For instance, a multicenter randomized controlled trial (INTRO-HCV) demonstrated that integrated treatment for hepatitis C among people who inject drugs (PWID) resulted in a notably higher rate of sustained virologic response (SVR), with 98% of participants initiating treatment compared to 77% in standard care (Fadnes et al., 2021). This study underscores the effectiveness of integrated care models that combine HCV treatment with support for substance use and mental health conditions. Further supporting this, a harm reduction-focused primary care program in New York City found that housing instability and Medicaid insurance were key predictors affecting treatment completion and follow-up for SVR testing (Ziff et al., 2021). This indicates that social determinants significantly influence treatment outcomes, thereby highlighting the necessity of integrated models that address these factors alongside medical treatment. Moreover, recent literature reviews indicate that patients with severe mental illness who are co-infected with HCV benefit from newer pangenotypic direct-acting antivirals, which have shown improved treatment adherence and outcomes (Gutiérrez-Rojas et al., 2023). Integrating psychiatric care into HCV treatment not only enhances medication adherence but also improves mental health outcomes, emphasizing the holistic benefits of such approaches. Despite these positive findings, many integrated treatment models remain underutilized due to structural barriers, provider shortages, and the stigma associated with both conditions (Adler et al., 2023). 4.0 DISCUSSION This literature review highlights the complex and bidirectional relationship between mental health disorders and hepatitis C virus (HCV) infection among people who use drugs (PWUD). The findings underscore that untreated mental health conditions significantly increase the risk of HCV acquisition, while chronic HCV infection can, in turn, exacerbate psychological distress through both biological mechanisms and psychosocial challenges. These findings carry important implications for clinical practice, public health programming, and policy development. 4.1 Mental Health Disorders and Increased Risk of HCV Repeating Connery et al. (2020) and Hashim et al. (2021), our findings attest that mental illness conditions such as depression, anxiety, bipolar disorder, and post-traumatic stress disorder (PTSD) are exceedingly common among drug users and play a major role in risky behaviors that spread HCV, including needle, cooker, and inhalation equipment sharing. Roncero et al. (2023) also add to this point by noting that dual disorders (the co-occurrence of substance use and mental illness) heighten these risks and advocate for treating both in clinical environments. The HCV prevalence among people with serious mental illness (SMI) continues to be a significant issue, with prevalence rates around 8%, which is up to 11 times greater than that of the general population. This is consistent with Braude et al. (2021), who report that mental illness is linked to poor attendance at harm reduction services and irregular use of sterile equipment, making HCV control more difficult. Gupta et al. (2022) further state that, in young PWID in rural New Mexico, PTSD has a significant effect on HCV infection through unsafe injection practices such as receptive syringe sharing (RSS), highlighting the importance of incorporating mental health services into harm reduction interventions. Beyond behavior, this review identifies the psychiatric and neurological effects of HCV infection, exacerbating underlying mental illness and resulting in cognitive impairment and increased anxiety. Overall health and treatment adherence are challenged by this reciprocal connection. As Rifai & Rosenstein (2005) note, stigma around mental illness and HCV both deter people from getting therapy, which feeds a vicious cycle of poor health. Aas et al. (2024) argue that while integrated HCV treatment is beneficial, it may not significantly reduce psychological suffering in patients with substance use disorders, requiring the use of specific mental health interventions in addition to HCV treatment. However, as Fuentes et al. (2022) note, HCV screening at mental health facilities is an intriguing intervention opportunity that could improve treatment and results for individuals with mental disorders. Recent Mendelian randomization studies, like Fu et al. (2024), provide evidence that mental illnesses, specifically bipolar disorder and schizophrenia, may raise the incidence of chronic HCV, indicating a complicated link that needs further investigation. Models like the Clubhouse model need to take social determinants of health (SDoH) into account to better understand the factors influencing mental health and HCV control. The need for complex interventions as shown by Kinney et al. (2022) advocates culturally relevant interventions that profoundly penetrate risk populations. When HCV co-occurs with co-occurring substance use disorders or mental disorders, combined care models have shown promise for improving patient outcomes and treatment uptake. Treatment compliance and general health are further complicated by this reciprocal interaction. Patients are discouraged from seeking treatment due to the stigma associated with mental health illnesses and HCV, which perpetuates the vicious cycle of poor health. Rifai and Rosenstein (2005). It is advised to use prescribed mental health interventions in addition to HCV therapy since, despite the potential benefits of an integrated model, an integrated treatment will not significantly relieve the mental health burden of the affected group (Aas et al., 2024). One novel intervention strategy that potentially enhance the treatment and results for individuals with mental illness is HCV screening in mental health settings (Fuentes et al. 2022). To understand the factors affecting mental health and HCV management in a better way, the Clubhouse model and others must also focus on social determinants of health (SDoH). Cultural interventions that investigate the risk communities call attention to the criticality of complex interventions Kinney et al. (2022). 4.2 Psychological Burden of Chronic HCV The impact of chronic HCV on mental health is very substantial. According to recent studies, anxiety and sadness may result from neuroinflammatory changes associated with HCV (Guo et al., 2023). Patients often experience severe psychological distress, which can show up as physical symptoms, fatigue, and cognitive impairment (Rashid et al., 2025). Ahmed et al. (2023) claims that the stigma surrounding HCV illness exacerbates social exclusion and denigration, which intensifies emotional distress and starts a vicious cycle in which psychological symptoms lower treatment compliance. The impact of chronic HCV on mental health is very substantial. Anxiety and depression may result from neuroinflammatory changes associated with HCV (Guo et al., 2023). According to Rashid et al. (2025), patients frequently experience severe psychological pain, which can manifest as physical symptoms, fatigue, and cognitive impairment. Emotional anguish is made worse by stigma associated with HCV, which increases social exclusion and humiliation. Because psychological symptoms lead to lower treatment adherence, this discomfort creates a vicious cycle (Ahmed et al., 2023). According to investigations, more than half of patients had low life satisfaction scores, suggesting that CHC patients typically experience lower levels of life satisfaction (Sierpińska, 2023). Additionally, among CHC patients, socioeconomic vulnerability attributes including homelessness and minority status are linked to elevated prescription opioid usage, which worsens their psychological distress (Butt et al., 2021). The very existence of this association emphasizes the relevance of incorporating mental and physical health into treatment plans. Notably, health-related quality of life and psychological well-being have been seen to improve after HCV elimination using direct-acting antiviral drugs (Bertino et al., 2021). This indicates that effective treatment can go a long way in relieving some of the mental health loads borne by patients. Additionally, the mediating effect of hope has been found to play a key role in promoting the quality of life of hepatitis patients, which implies that the promotion of positive emotional states can buffer psychological distress (Bano et al., 2024). The relationship between chronic HCV and mental health is bidirectional and complex. To improve overall outcomes for people with chronic hepatitis C, mental health services must be integrated into hepatitis care, social support must be encouraged, and psychological symptoms must be treated. Our findings corroborate the recent study conducted by Guo et al. (2023), demonstrating that neuroinflammatory processes associated with chronic HCV infection play a role in the pathophysiology of depressive and anxiety symptoms. These findings align with Rashid et al. (2025), who explain that changes in neuroinflammation can lead to cognitive impairment, chronic fatigue, and somatic symptoms, which additionally complicate the mental health scenario in such patients. The psychological burden of HCV infection often exacerbates social disengagement and shame, making it difficult for people to get much-needed medical care. This stigma is reinforced by Ahmed et al. (2023), who point out that the stress of having a stigmatized, incurable ailment can result in social isolation and poverty, particularly for people who are already dealing with a mental problem. Taye's (2021) claim that co-occurring disorders frequently provide obstacles to successful treatment adherence is supported by the self-reinforcing loop that these psychological issues produce, which may significantly reduce treatment adherence. The idea that co-morbid conditions frequently create obstacles to efficient treatment adherence is supported by the self-reinforcing nature of the psychological problems that arise, which may drastically lower treatment adherence. (Taye, 2021). Furthermore, our data suggest that individuals with chronic hepatitis C also frequently have reduced life satisfaction, a finding that Sierpińska (2023) supported, as more than half of patients had low satisfaction levels. Butt et al. (2021) also finds a link between social vulnerability characteristics, homelessness, minority status and increased psychological challenges, supporting the need for dual treatment approaches that address mental and physical health. Interestingly, health-related quality of life and psychological well-being improvements after HCV elimination using direct-acting antiviral drugs have been reported (Bertino et al., 2021). The belief is that patients' mental health burdens may be mitigated with effective therapy. Our review demonstrates that fostering pleasant emotional states, as mentioned by Bano et al. (2024), can be crucial in alleviating psychological discomfort. This suggests that mental health remedies should be included in hepatitis treatment. 4.3 Integrated Models of Care When it comes to treating serious mental illness, substance use disorders, and the hepatitis C virus (HCV), integrated care models have demonstrated great promise. Coordinated mental health and HCV services have been linked to improved psychological outcomes, increased treatment completion rates, and enhanced patient involvement (Mahoney et al., 2024). For example, Braude et al. (2023) analyzed the care cascade at a tertiary health facility and demonstrated the efficacy of a pilot "identify and treat" method for HCV among people with severe mental illness. According to their findings, specific strategies may improve treatment adherence in this susceptible group. Additionally, patients who inject drugs have found success with patient-centered models of care, proving that tailored treatment plans can improve health outcomes (Litwin et al., 2022). These methods improve patients' adherence to treatment plans by focusing on their needs and situations. Nevertheless, integrated care models are still not widely used, especially in settings with limited resources, despite the encouraging outcomes. Scalability and sustainability are restricted by structural obstacles, such as provider shortages, disjointed health systems, and enduring stigma (Schwarz et al., 2022). Improving care access and outcomes for people with HCV and co-occurring illnesses depends on addressing these issues. Integrated approaches are particularly critical in high-risk settings such as the criminal justice system, where the co-occurrence of opioid use disorder, mental illness, and infectious diseases like HCV is common and continuity of care is frequently disrupted (Winetsky et al., 2020). Although integrated care models provide a way ahead for controlling HCV and associated comorbidities, more work is required to get over current challenges and guarantee that these models are broadly accepted and successfully put into practice. The results of integrated care models demonstrate the advantages of treating hepatitis C virus (HCV) and mental health at the same time, improving both conditions. Our results are consistent with those of Mahoney et al. (2024), who indicate improved mental health outcomes, increased rates of sustained virologic response (SVR), and greater drug adherence among patients getting integrated care with embedded psychological support. This lends credence to the idea that integrated strategies might greatly improve HCV treatment efficacy. For example, integrated therapy for hepatitis C among individuals who inject drugs (PWID) led to a much higher SVR rate; 98% of patients started treatment compared to 77% in standard care, according to the multicenter randomized controlled study (INTRO-HCV) (Fadnes et al., 2021). This result is consistent with the findings of Braude et al. (2023), who demonstrated the effectiveness of a pilot "identify and treat" approach in a tertiary health care for patients with severe mental illness. These focused strategies imply that integrated care can successfully increase treatment uptake in susceptible groups, highlighting the advantages of linked HCV and mental health services. Furthermore, our analysis highlights how important social variables are in determining treatment outcomes. Housing instability and Medicaid insurance were found to be important determinants of treatment completion and SVR test follow-up in the harm reduction-focused program in New York City (Ziff et al., 2021). This is consistent with the findings of Schwarz et al. (2022), who point out that structural obstacles, like a lack of providers and disjointed health systems, restrict the scalability of integrated care models, especially in environments with limited resources. Furthermore, novel pangenotypic direct-acting antivirals have been shown to increase treatment adherence and outcomes for patients with severe mental illness co-infected with HCV (Gutiérrez-Rojas et al., 2023). This highlights the significance of incorporating psychiatric care into HCV treatment since it improves general mental health and increases medication adherence, highlighting a patient-centered approach. Many integrated care methods are still underutilized despite the encouraging results regarding them because of the ongoing stigma attached to both HCV and mental health issues (Adler et al., 2023). This stigma might discourage people from getting help and participating in supportive care, underscoring the critical need for all-encompassing solutions to these problems. The management of the overlapping problems of substance use disorders, mental health diseases, and the hepatitis C virus (HCV) has significantly improved thanks to integrated care methods. Coordinated mental health and HCV care have been associated with better psychological outcomes, increased treatment completion rates, and increased patient participation (Mahoney et al., 2024). The efficacy of a pilot "identify and treat" strategy for HCV in individuals with severe mental illness was highlighted by a care cascade analysis at a tertiary health service (Braude et al., 2023). These findings suggest that targeted treatments can increase this high-risk population's adherence to treatment. Customized approaches can result in better health outcomes, as evidenced by the effectiveness of patient-centered care models for injecting drug users (Litwin et al., 2022). Even with these developments, integrated care models remain underutilized, particularly in settings with limited resources. Their growth and long-term survival are hampered by significant challenges like a lack of workers, disjointed healthcare systems, and enduring stigma (Schwarz et al., 2022). New research supports the benefits of treating HCV and mental health issues at the same time, leading to synergistic gains in both areas. Our findings are consistent with those of Mahoney et al. (2024), who discovered improved mental health indicators, higher sustained virologic response (SVR) rates, and better drug adherence among patients getting coordinated care with integrated psychiatric assistance. This highlights how coordinated approaches can significantly improve the effectiveness of HCV treatment. For example, integrated HCV treatment for individuals who inject drugs (PWID) obtained an SVR rate with 98% treatment initiation compared to 77% in standard care, according to the multicenter INTRO-HCV randomized controlled study (Fadnes et al., 2021). This corroborates the findings of Braude et al. (2023), whose trial "identify and treat" program in a tertiary setting effectively raised uptake among those with severe mental illness. These focused initiatives confirm that integrated care can increase participation in vulnerable populations, enhancing the benefits of coordinated HCV and mental health services. Our analysis also emphasizes how important social variables are to the effectiveness of treatment. Housing instability and Medicaid coverage were identified by a harm reduction program in New York City as key determinants of treatment completion and SVR follow-up (Ziff et al., 2021). These observations are consistent with those of Schwarz et al. (2022), who noted structural obstacles to scaling integrated models in low-resource situations, including as provider shortages and disjointed systems. According to recent research, current pangenotypic direct-acting antivirals improve adherence and overall results in patients with severe mental illness and HCV co-infection (Gutiérrez-Rojas et al., 2023). 4.4 Research Gaps and Limitations Although the reviewed literature provides valuable insights, several gaps remain: I. Lack of longitudinal evidence : Most studies were cross-sectional, limiting understanding of causality and temporal trends. II. Limited population diversity : Research rarely disaggregated findings by gender, age, race/ethnicity, or socioeconomic status. III. Underrepresentation of qualitative perspectives : The voices of individuals living with co-occurring disorders are largely absent from existing research. IV. Variable quality of evidence : Some studies lacked standardized measurement tools or had small sample sizes, limiting generalizability. 5.0 CONCLUSION The evidence reviewed in this study reinforces the urgent need to address the bidirectional relationship between mental health disorders and hepatitis C virus (HCV) infection among people who use drugs (PWUD). Mental health challenges significantly elevate the risk of HCV transmission through risky behaviors and poor adherence to treatment, while chronic HCV infection contributes to psychological distress through biological and psychosocial mechanisms. Integrated treatment approaches that address both conditions simultaneously offer a promising path forward. However, their implementation remains limited due to structural barriers, under-resourcing, and stigma. Bridging this gap will require coordinated efforts across disciplines psychiatry, infectious diseases, public health, and substance use treatment. Future research should prioritize longitudinal and population-specific studies, as well as mixed-methods and qualitative approaches that center on the experiences of those most affected. Ultimately, advancing integrated care models and evidence-based policy interventions will be critical to improving health outcomes for this vulnerable population and achieving global HCV elimination goals. Declarations Availability of Data and Materials Consent to participate Not applicable Consent to publish Not applicable. This study does not contain any individual person’s data in any form. Ethics statement As this review utilized publicly available data from previously published studies, no ethical approval was required. Clinical Trial Number Not applicable Funding Declaration The authors declare that this research received no funding Declaration of Interest Statement The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. Ethical Accordance This narrative review solely relies on the abundance of already published, publicly available research, so no fresh primary data nor direct human participation were gathered. As a result, official ethical approval was not obtained. However, we conducted this synthesis with a thorough dedication to academic integrity, paying close attention to the confidentiality guidelines and ethical clearances that the original researchers had already set. To ensure that our study is primarily in its commitment to ethical scholarship even though it is secondary in nature, our work seeks to acknowledge what they have accomplished through transparent acknowledgment. References Ahmed, M., Cerda, I., & Maloof, M. (2023). Breaking the vicious cycle: The interplay between loneliness, metabolic illness, and mental health. Frontiers in Psychiatry, 14 , 1134865. https://doi.org/10.3389/fpsyt.2023.1134865 Baingana, F., al’Absi, M., Becker, A. E., & Pringle, B. (2015). Global research challenges and opportunities for mental health and substance-use disorders. Nature, 527 (7578), S172–S177. https://doi.org/10.1038/nature16032 Braude, M. R., Phan, T., Dev, A., & Sievert, W. (2021). Determinants of hepatitis C virus prevalence in people with serious mental illness: A systematic review and meta-analysis. The Journal of Clinical Psychiatry, 83 (1), 21r14079. https://doi.org/10.4088/JCP.21r14079 Centers for Disease Control and Prevention. (2024, June 10). Global viral hepatitis . https://www.cdc.gov/hepatitis/global/index.html Connery, H. S., McHugh, R. K., Reilly, M., Shin, S., & Greenfield, S. F. (2020). Substance use disorders in global mental health delivery: Epidemiology, treatment gap, and implementation of evidence-based treatments. Harvard Review of Psychiatry, 28 (5), 316–327. https://doi.org/10.1097/HRP.0000000000000271 Guo, B., Zhang, M., Hao, W., Wang, Y., Zhang, T., & Liu, C. (2023). Neuroinflammation mechanisms of neuromodulation therapies for anxiety and depression. Translational Psychiatry, 13 (1), 5. https://doi.org/10.1038/s41398-022-02297-y Faccioli, J., Nardelli, S., Gioia, S., Riggio, O., & Ridola, L. (2021). Neurological and psychiatric effects of hepatitis C virus infection. World Journal of Gastroenterology , 27 (29), 4846–4861. https://doi.org/10.3748/wjg.v27.i29.4846 Hashim, A., Macken, L., Jones, A., et al. (2021). Community-based assessment and treatment of hepatitis C virus-related liver disease, injecting drug and alcohol use amongst people who are homeless: A systematic review and meta-analysis. International Journal of Drug Policy, 96 , 103342. https://doi.org/10.1016/j.drugpo.2021.103342 Mahoney, B. J., Morford, K. L., Biegacki, E. T., & Tetrault, J. M. (2024). Hepatitis C virus and integrated care for substance use disorders. Clinical Liver Disease (Hoboken), 23 (1), e0241. https://doi.org/10.1097/CLD.0000000000000241 National Institute on Drug Abuse. (2020). Common comorbidities with substance use disorders research report . https://www.drugabuse.gov/publications/research-reports/common-comorbidities-with-substance-use-disorders/part-1-connection-between-substance-use-disorders-mental-illness Understanding the link between chronic disease and depression—National institute of Mental Health (NIMH). (n.d.). Retrieved November 11, 2025, from https://www.nimh.nih.gov/health/publications/chronic-illness-mental-health Hepatitis c. (n.d.). Retrieved November 11, 2025, from https://www.who.int/news-room/fact-sheets/detail/hepatitis-c Bano, M., Hussain, S., Rida Mehmood, H., Arshad, O., & Sher, A. (2024). Psychological distress and quality of life in hepatitis patients: The mediating role of hope. Journal of Asian Development Studies , 13 (3), 1092–1100. https://doi.org/10.62345/jads.2024.13.3.89 Braude, M., Phan, T., Con, D., Woolley, I., Sundram, S., Clarke, D., Dev, A., & Sievert, W. (2023). Hepatitis C virus in people with serious mental illness: An analysis of the care cascade at a tertiary health service with a pilot ‘identify and treat’ strategy. Internal Medicine Journal , 53 (5), 700–708. https://doi.org/10.1111/imj.15604 Butt, A. A., Yan, P., Kapadia, S., Abou-Samra, A.-B., Janjua, N. Z., & Ibrahim, S. (2021). Social vulnerability in persons with chronic hepatitis C virus infection is associated with a higher risk of prescription opioid use. Scientific Reports , 11 (1), 5883. https://doi.org/10.1038/s41598-021-85283-6 Fu, H., Jiang, S., Song, S., Zhang, C., & Xie, Q. (2024). Causal associations between chronic viral hepatitis and psychiatric disorders: A Mendelian randomization study. Frontiers in Psychiatry , 15 , 1359080. https://doi.org/10.3389/fpsyt.2024.1359080 Kinney, A. R., Bahraini, N., Donovan, M. L., & Brenner, L. A. (2022). Characterizing social determinants of health in research regarding the clubhouse model for individuals with mental health conditions. Current Treatment Options in Psychiatry , 9 (4), 376–405. https://doi.org/10.1007/s40501-022-00274-2 Litwin, A. H., Lum, P. J., Taylor, L. E., Mehta, S. H., Tsui, J. I., Feinberg, J., Kim, A. Y., Norton, B. L., Heo, M., Arnsten, J., Meissner, P., Karasz, A., Mckee, M. D., Ward, J. W., Johnson, N., Pericot-Valverde, I., Agyemang, L., Stein, E. S., Thomas, A., … Page, K. (2022). Patient-centred models of hepatitis C treatment for people who inject drugs: A multicentre, pragmatic randomised trial. The Lancet Gastroenterology & Hepatology , 7(12), 1112–1127. https://doi.org/10.1016/S2468-1253(22)00275-8 Mahoney, B. J., Morford, K. L., Biegacki, E. T., & Tetrault, J. M. (2024). Hepatitis C virus and integrated care for substance use disorders. Clinical Liver Disease, 23(1). https://doi.org/10.1097/CLD.0000000000000241 Marcellusi, A., Simonelli, C., Mennini, F. S., Kondili, L. A., & PITER Collaborating Group available at http://www.progettopiter.it. (2022). Economic consequences of anti-hcv treatment of patients diagnosed through screening in italy: A prospective modelling analysis. Applied Health Economics and Health Policy , 20 (1), 133–143. https://doi.org/10.1007/s40258-021-00677-x Polukchi, T. V., Abuova, G. N., & Slavko, Y. A. (2023). The neuropsychiatric aspect of chronic viral hepatitis. Prague Medical Report , 124 (2), 94–107. https://doi.org/10.14712/23362936.2023.8 Rashid, A. A., Rashid, A., Zahra, M., Aslam, N., Jameel, S., Awais, H. M., & Zaheer, H. (2025). Psychosomatic and psychological impact of hepatitis c: A cross-sectional study of depression, fibrosis, and somatic symptoms in treatment-naive and treatment-experienced patients who achieved sustained virologic response. Cureus . https://doi.org/10.7759/cureus.80104 Rifai, M. A., & Rosenstein, D. L. (2005). Hepatitis C and psychiatry. Focus , 3 (2), 194–202. https://doi.org/10.1176/foc.3.2.194 Schwarz, T., Horváth, I., Fenz, L., Schmutterer, I., Rosian-Schikuta, I., & Mårdh, O. (2022). Interventions to increase linkage to care and adherence to treatment for hepatitis C among people who inject drugs: A systematic review and practical considerations from an expert panel consultation. International Journal of Drug Policy , 102 , 103588. https://doi.org/10.1016/j.drugpo.2022.103588 Sierpińska, L. E. (2023). Assessment of the level of life satisfaction and health behaviors among patients with chronic hepatitis c. American Journal of Health Behavior , 47 (3), 595–604. https://doi.org/10.5993/AJHB.47.3.17 Sulkowski, M., Ionescu-Ittu, R., Macaulay, D., & Sanchez-Gonzalez, Y. (2020). The economic value of improved productivity from treatment of chronic hepatitis c virus infection: A retrospective analysis of earnings, work loss, and health insurance data. Advances in Therapy , 37 (11), 4709–4719. https://doi.org/10.1007/s12325-020-01492-x Yang, J., Qi, J.-L., Wang, X.-X., Li, X.-H., Jin, R., Liu, B.-Y., Liu, H.-X., & Rao, H.-Y. (2023a). The burden of hepatitis C virus in the world, China, India, and the United States from 1990 to 2019. Frontiers in Public Health , 11, 1041201. https://doi.org/10.3389/fpubh.2023.1041201O Roncero, C., Buch-Vicente, B., Martín-Sánchez, Á. M., Álvarez-Navares, A. I., Andrés-Olivera, P., Gamonal-Limcaoco, S., Lozano-López, M. T., Aguilar, L., Sánchez-Casado, F., & García-Ullán, L. (2023). Prevalence of hepatitis C virus infection in patients with chronic mental disorders: The relevance of dual disorders. Gastroenterología y Hepatología (English Edition) , 46 (3), 171–177. https://doi.org/10.1016/j.gastre.2022.06.005 Gupta, A., Shebl, F. M., Tong, Y., Wagner, K., Bassett, I. V., Page, K., & Winstanley, E. L. (2022). Association of co-occurring mental health problems with hepatitis C status among young people who inject drugs in rural New Mexico, 2016–2018. Addiction Science & Clinical Practice , 17 (1), 58. https://doi.org/10.1186/s13722-022-00340-3 Aas, C. F., Vold, J. H., Chalabianloo, F., Løberg, E.-M., Lim, A. G., Vickerman, P., Johansson, K. A., & Fadnes, L. T. (2024). Effect of integrated hepatitis C virus treatment on psychological distress in people with substance use disorders. Scientific Reports , 14 (1), 816. https://doi.org/10.1038/s41598-024-51336-9 Okobi, O. E., Ayo-Farai, O., Tran, M., Ibeneme, C., Ihezie, C. O., Ezie, O. B., & Adeakin-Dada, T. O. (2024). The impact of infectious diseases on psychiatric disorders: A systematic review. Cureus . https://doi.org/10.7759/cureus.66323 Flisiak, R., Rzymski, P., Flisiak-Jackiewicz, M., Brzdęk, M., & Zarębska-Michaluk, D. (2025). Treatment of chronic hepatitis C infection: Strategies to address poor therapy adherence. Expert Review of Anti-Infective Therapy , 23 (6), 379–387. https://doi.org/10.1080/14787210.2025.2486353 Taye, B. W. (2021). Hepatitis C virus infection and tobacco smoking - joint health effects and implications for treatment of both: A systematic review . https://doi.org/10.1101/2021.10.12.21264923 Piekut, T., Hurła, M., Banaszek, N., Szejn, P., Dorszewska, J., Kozubski, W., & Prendecki, M. (2022). Infectious agents and Alzheimer’s disease. Journal of Integrative Neuroscience , 21 (2), 73. https://doi.org/10.31083/j.jin2102073 Winetsky, D., Fox, A., Nijhawan, A., & Rich, J. D. (2020). Treating opioid use disorder and related infectious diseases in the criminal justice system. Infectious Disease Clinics of North America , 34 (3), 585–603. https://doi.org/10.1016/j.idc.2020.06.012 Fadnes, L. T., Aas, C. F., Vold, J. H., Leiva, R. A., Ohldieck, C., Chalabianloo, F., Skurtveit, S., Lygren, O. J., Dalgård, O., Vickerman, P., Midgard, H., Løberg, E.-M., Johansson, K. A., & for the INTRO-HCV Study Group. (2021). Integrated treatment of hepatitis C virus infection among people who inject drugs: A multicenter randomized controlled trial (Intro-hcv). PLOS Medicine , 18 (6), e1003653. https://doi.org/10.1371/journal.pmed.1003653 Ziff, J., Vu, T., Dvir, D., Riazi, F., Toribio, W., Oster, S., Sigel, K., & Weiss, J. (2021). Predictors of hepatitis C treatment outcomes in a harm reduction-focused primary care program in New York City. Harm Reduction Journal , 18 (1), 38. https://doi.org/10.1186/s12954-021-00486-4 Gutiérrez-Rojas, L., De La Gándara Martín, J. J., García Buey, L., Uriz Otano, J. I., Mena, Á., & Roncero, C. (2023). Patients with severe mental illness and hepatitis C virus infection benefit from new pangenotypic direct-acting antivirals: Results of a literature review. Gastroenterología y Hepatología (English Edition) , 46 (5), 382–396. https://doi.org/10.1016/j.gastre.2022.06.009 Adler, A. J., Drown, L., Boudreaux, C., Coates, M., Marx, A., Akala, O., Waqanivalu, T., Xu, H., & Bukhman, G. (2023). Understanding integrated service delivery: A scoping review of models for noncommunicable disease and mental health interventions in low-and-middle income countries. BMC Health Services Research , 23 (1), 99. https://doi.org/10.1186/s12913-023-09072-9 Tables Table 1 : Summary of selected studies demonstrating the interaction between mental health disorders and hepatitis C virus infection among people who use drugs. SMI = Serious Mental Illness; SUD = substance use disorder; PWUD = People Who Use Drugs; HCV = Hepatitis C Virus. Author(s) (Year) Study Design Population Focus Key Findings Relevant to HCV & Mental Health Braude et al. (2021) Systematic Review & Meta-analysis Individuals with Serious Mental Illness (SMI) In SMI communities, the prevalence of HCV is approximately 8%, which is up to 11 times greater than in the general population. Connery et al. (2020) Epidemiological Overview Global populations with substance use disorders (SUD) Approximately 40% of drug users fit the criteria for a co-occurring mental health condition. Roncero et al. (2023) Cross-sectional Study Patients with chronic mental disorders Due to increased rates of risky behaviors (such as sharing syringes), dual illnesses (mental illness + substance use) dramatically raise the risk of HCV. Gupta et al. (2022) Cohort Study Young PWID in rural New Mexico Receptive syringe sharing (RSS) is one of the dangerous injection practices that mediates the considerable influence of PTSD on HCV infection rates. Guo et al. (2023) Mechanistic Review Patients with HCV and depression Neuroinflammation linked to chronic HCV plays a role in the pathophysiology of anxiety and depression symptoms. Ahmed et al. (2023) Review Individuals with chronic illness & mental health conditions The stigma associated with HCV exacerbates mental illnesses and impedes care engagement by causing social isolation and despondency. Fadnes et al. (2021) (INTRO-HCV) Randomized Controlled Trial People who inject drugs (PWID) Compared to 77% in normal care, integrated HCV treatment, which combines medical, mental health, and SUD support, achieved 98% treatment initiation. Mahoney et al. (2024) Narrative Review PWUD in integrated care settings Mental health outcomes, sustained virologic response (SVR) rates, and drug adherence are all enhanced by integrated care models. Ziff et al. (2021) Observational Study PWUD in a harm reduction primary care program The completion and follow-up of HCV therapy are significantly predicted by social variables, such as housing instability and insurance type. Aas et al. (2024) Intervention Study People with substance use disorders By lowering psychological discomfort, integrated HCV treatment may lessen the likelihood of HCV transmission. Gutiérrez-Rojas et al. (2023) Literature Review Patients with severe mental illness & HCV In this co-infected group, new pangenotypic direct-acting antivirals enhance treatment compliance and results. Hashim et al. (2021) Meta-analysis Homeless PWUD This brings attention to the significant prevalence of HCV and poor mental health, highlighting the necessity of coordinated community-based interventions. Table 2. Selected studies demonstrating the interaction between mental health disorders and hepatitis C virus infection among people who use drugs. SMI = Serious Mental Illness; SUD = substance use disorder; PWUD = People Who Use Drugs; HCV = Hepatitis C Virus. Author(s) Year Study Type Population Key Findings Braude et al. 2021 Systematic Review Individuals with SMI HCV prevalence 3–11x higher in SMI populations Connery et al. 2020 Epidemiological Overview Global populations with SUD 40% of drug users have mental health disorders Mahoney et al. 2024 Narrative Review PWUD in integrated care Integrated care improves adherence and treatment outcomes Hashim et al. 2021 Meta-analysis Homeless PWUD High HCV burden, poor mental health, need for community-based interventions Guo et al. 2023 Mechanistic Review Patients with HCV and depression Neuroinflammation linked to mental health symptoms in chronic HCV Additional Declarations No competing interests reported. Cite Share Download PDF Status: Posted Version 1 posted You are reading this latest preprint version Research Square lets you share your work early, gain feedback from the community, and start making changes to your manuscript prior to peer review in a journal. As a division of Research Square Company, we’re committed to making research communication faster, fairer, and more useful. We do this by developing innovative software and high quality services for the global research community. Our growing team is made up of researchers and industry professionals working together to solve the most critical problems facing scientific publishing. Also discoverable on Platform About Our Team In Review Editorial Policies Advisory Board Help Center Resources Author Services Accessibility API Access RSS feed Manage Cookie Preferences © Research Square 2026 | ISSN 2693-5015 (online) Privacy Policy Terms of Service Do Not Sell My Personal Information {"props":{"pageProps":{"initialData":{"identity":"rs-8702097","acceptedTermsAndConditions":true,"allowDirectSubmit":true,"archivedVersions":[],"articleType":"Systematic Review","associatedPublications":[],"authors":[{"id":600109198,"identity":"4682cf1a-8a2a-4891-9534-f540d79b8178","order_by":0,"name":"Perseverance N Moyo","email":"data:image/png;base64,iVBORw0KGgoAAAANSUhEUgAAAZAAAAAyAQMAAABI0h/eAAAABlBMVEX///8AAABVwtN+AAAACXBIWXMAAA7EAAAOxAGVKw4bAAAAxUlEQVRIiWNgGAWjYPACGxk2CRj7AHFa0njAWg6QoOUwDwPRWsyluxMf81Sc5+GTbj72+WMbgxzfjQT8WiznnN1szHPmNg+bzLHkGQfbGIwlCWkxuJG7TZq3DahFIseYAaglcQORWs4BteR/BmmpJ1bLAZAtzCAtCQYE/TIjd7PhnDPJIL8YM5w5J2E488wD/FrMJXI3PnhTYScnP7v5MUNFmY0833FCDgNiJh4YjxGRBvBrYfwB5/4hrGMUjIJRMApGHgAAvfFD+4CjmpYAAAAASUVORK5CYII=","orcid":"","institution":"Liberty University","correspondingAuthor":true,"prefix":"","firstName":"Perseverance","middleName":"N","lastName":"Moyo","suffix":""},{"id":600109199,"identity":"1bb17d38-0e93-4296-b702-d845638ba166","order_by":1,"name":"David S.O Abafi","email":"","orcid":"","institution":"","correspondingAuthor":false,"prefix":"","firstName":"David","middleName":"S.O","lastName":"Abafi","suffix":""},{"id":600109200,"identity":"fe09682d-9ae1-470c-8847-42fbef475b12","order_by":2,"name":"Becky Masele","email":"","orcid":"","institution":"","correspondingAuthor":false,"prefix":"","firstName":"Becky","middleName":"","lastName":"Masele","suffix":""},{"id":600109201,"identity":"0aa6a842-8f20-4312-b6c7-77150c4f0336","order_by":3,"name":"Wuraola R. Awosan","email":"","orcid":"","institution":"Liberty University","correspondingAuthor":false,"prefix":"","firstName":"Wuraola","middleName":"R.","lastName":"Awosan","suffix":""},{"id":600109202,"identity":"f828f0b2-e7fc-4180-aab9-bac047131efc","order_by":4,"name":"Thomas Kerkering","email":"","orcid":"","institution":"","correspondingAuthor":false,"prefix":"","firstName":"Thomas","middleName":"","lastName":"Kerkering","suffix":""}],"badges":[],"createdAt":"2026-01-26 15:54:16","currentVersionCode":1,"declarations":"","doi":"10.21203/rs.3.rs-8702097/v1","doiUrl":"https://doi.org/10.21203/rs.3.rs-8702097/v1","draftVersion":[],"editorialEvents":[],"editorialNote":"","failedWorkflow":false,"files":[{"id":103919785,"identity":"08233100-748f-4ba0-8070-8089391d58bb","added_by":"auto","created_at":"2026-03-04 13:57:55","extension":"png","order_by":1,"title":"Figure 1","display":"","copyAsset":false,"role":"figure","size":60444,"visible":true,"origin":"","legend":"\u003cp\u003eDistribution of articles identified using major keyword combinations related to hepatitis C and mental health disorders among people who use drugs (PWUD). Numbers reflect initial results from database searches (PubMed, PsycINFO, Google Scholar) prior to application of inclusion criteria.\u003c/p\u003e","description":"","filename":"1.png","url":"https://assets-eu.researchsquare.com/files/rs-8702097/v1/b9f8e88dcacc798b3f08a942.png"},{"id":108976509,"identity":"e38511a8-455f-4e49-91bd-452ab58efaf4","added_by":"auto","created_at":"2026-05-11 11:23:45","extension":"pdf","order_by":0,"title":"","display":"","copyAsset":false,"role":"manuscript-pdf","size":378036,"visible":true,"origin":"","legend":"","description":"","filename":"manuscript.pdf","url":"https://assets-eu.researchsquare.com/files/rs-8702097/v1/cd084e95-5eaa-4cbd-acc8-df6e92081edb.pdf"}],"financialInterests":"No competing interests reported.","formattedTitle":"\u003cp\u003eThe Bidirectional Relationship Between Mental Health Disorders and Hepatitis C Virus (Hcv) Among Drug Users\u003c/p\u003e","fulltext":[{"header":"1.0 INTRODUCTION","content":"\u003cp\u003eOver 3,500 people die every day from hepatitis C virus (HCV) infection, and there are approximately 1\u0026nbsp;million new cases of hepatitis B and C combined reported worldwide each year, highlighting the seriousness of this disease as a major global health concern (World Health Organization [WHO], 2025; Centers for Disease Control and Prevention [CDC], 2024). HCV is a major cause of liver-related disease and mortality, such as cirrhosis and hepatocellular carcinoma, and it presently affects an estimated 50\u0026nbsp;million individuals globally. HCV is a major cause of liver-related disease and mortality, such as cirrhosis and hepatocellular carcinoma, and it presently affects an estimated 50\u0026nbsp;million individuals globally, representing a substantial global disease burden across regions including the United States and other heavily affected countries (Yang et al., 2023). The development of effective antiviral treatments has advanced significantly, most notably with the introduction of direct-acting antivirals (DAAs), which have fewer side effects and high cure rates than earlier treatments. Nevertheless, there are still significant gaps in diagnosis, treatment access, and care engagement. (CDC, 2024). For example, less than 20% of those living with HCV have received curative treatment with DAAs, and less than 40% of them are aware of their infection status worldwide (CDC, 2024). Among high-risk groups, such as drug users (PWUD), where stigma, concurrent mental health disorders, structural hurdles, and poor access to healthcare make vulnerability worse these disparities are particularly noticeable. Mental health and substance use disorders are increasingly recognized as major global public health priorities due to their high prevalence, substantial treatment gaps, and close interaction with other chronic diseases, particularly among vulnerable populations such as people who use drugs (Baingana et al., \u003cspan citationid=\"CR2\" class=\"CitationRef\"\u003e2015\u003c/span\u003e). The high incidence and disproportionate health impact of HCV in these regions this population underscores the pressing need for integrated care models and focused public health initiatives to enhance screening, care linkage, and treatment results (CDC, 2024).\u003c/p\u003e \u003cp\u003eHepatitis C virus (HCV) infection, mental illness, and substance usage combine to create a complicated and mutually reinforcing triple threat that has significant effects on both public and individual health outcomes. Hepatitis C virus (HCV) infection, mental illness, and substance use frequently co-occur among people who use drugs and together contribute to elevated risk behaviors, reduced access to care, and poorer treatment outcomes. The prevalence of HCV among people who inject drugs (PWID) is still astonishingly high, frequently surpassing 50% in several environments. High-risk practices that promote effective viral transmission, such as sharing syringes, needles, and other contaminated injection supplies, are mostly to blame for this increased rate (Hashim et al., \u003cspan citationid=\"CR8\" class=\"CitationRef\"\u003e2021\u003c/span\u003e). However, infectious diseases are not the only health problems this population faces. Mental health conditions like depression, anxiety, PTSD, and psychotic disorders are very common among drug users and these co-occurring psychiatric conditions not only make substance use behaviors worse but also pose major obstacles to accessing healthcare services like HCV screening, diagnosis, and treatment adherence.( Connery et al. (\u003cspan citationid=\"CR5\" class=\"CitationRef\"\u003e2020\u003c/span\u003e) also note that approximately 40% of people who use drugs (PWUD) fulfill the diagnostic criteria for at least one mental health issue, and nearly half of people with serious mental illness (SMI) also use drugs problematically. Aside from making treatment more difficult, this co-morbidity increases the burden of disease and emphasizes the necessity of integrated, multidisciplinary methods to care that concurrently address infectious disease and mental health.\u003c/p\u003e \u003cp\u003eIt is becoming well acknowledged that there is a bidirectional association between hepatitis C virus (HCV) infection and mental health disorders, with important ramifications for long-term results, prevention, and treatment. Those with mental health conditions are more likely to contract HCV, especially those that involve emotional dysregulation, a history of trauma, cognitive deficits, or impulsiveness. These vulnerabilities frequently manifest as increased substance use, high-risk injection behaviors, and noncompliance with treatment or prevention plans (Mahoney et al., \u003cspan citationid=\"CR9\" class=\"CitationRef\"\u003e2024\u003c/span\u003e; Khan et al., 2024). Particularly among people who inject drugs (PWID), concomitant mental illnesses including depression, anxiety, or post-traumatic stress disorder (PTSD) might affect judgment and self-care practices, making it more likely that they will be exposed to HCV in high-risk settings (Khan et al., 2024). Conversely, there are several ways in which persistent HCV infection can either cause or exacerbate mental health issues. Biologically, HCV can cause hepatic encephalopathy, immunological dysregulation, and neuroinflammation; these conditions have all been linked to fluctuations in mood, exhaustion, and cognitive impairment (Guo et al., \u003cspan citationid=\"CR6\" class=\"CitationRef\"\u003e2023\u003c/span\u003e; Ahmed et al., \u003cspan citationid=\"CR1\" class=\"CitationRef\"\u003e2023\u003c/span\u003e). Psychosocially, having chronic, stigmatized illness can cause psychological anguish, low self-esteem, and social isolation. Furthermore, new research indicates that HCV may have direct neurotropic effects, affecting the functioning of the central nervous system even when there is no advanced liver disease. This could lead to cognitive decline, depression symptoms, and a lower quality of life (Faccioli et al., \u003cspan citationid=\"CR7\" class=\"CitationRef\"\u003e2021\u003c/span\u003e).\u003c/p\u003e \u003cp\u003eThe combination of substance use, mental health issues, and hepatitis C virus (HCV) greatly increases the chance of reinfection and worsens morbidity, in addition to making diagnosis and treatment more difficult. This increases the likelihood that patients would stop using healthcare services, interrupt treatment courses, and not take their medications as directed. This increases the likelihood that patients will disengage from healthcare services, experience interruptions in treatment courses, and demonstrate poor medication adherence. This compromises not only clinical results but also the advancement of public health objectives, such the WHO's HCV eradication ambitions. The consequences are not just clinical but also financial, placing a significant strain on healthcare systems around the world (Sulkowski et al. \u003cspan citationid=\"CR26\" class=\"CitationRef\"\u003e2020\u003c/span\u003e). Based on the severity of the disease, annual healthcare costs for people with chronic HCV can vary greatly, from about \u003cspan\u003e$\u003c/span\u003e10,561 for those without cirrhosis to over \u003cspan\u003e$\u003c/span\u003e46,000 for those with advanced liver disease, such as cirrhosis or hepatocellular carcinoma (Sulkowski et al., \u003cspan citationid=\"CR26\" class=\"CitationRef\"\u003e2020\u003c/span\u003e). These expenses cover hospital stays, diagnostic procedures, antiviral therapy, outpatient visits, and the handling of problems. These expenses are frequently overshadowed by the high upfront costs of direct-acting antivirals (DAAs) and the systemic difficulties in enrolling and keeping underserved populations in care, even though the introduction of DAAs has greatly increased cure rates and decreased long-term costs, resulting in savings of about \u003cspan\u003e$\u003c/span\u003e15,900 per patient annually following successful treatment (Marcellusi et al., \u003cspan citationid=\"CR20\" class=\"CitationRef\"\u003e2022\u003c/span\u003e).\u003c/p\u003e \u003cp\u003eTo tackle this complex problem, we must move toward integrated, multidisciplinary care approaches that take the social, psychological, and medical requirements of PWUD into account. Separate treatments Siloed care approaches are insufficient in this population since mental health conditions and HCV are syndetic. To improve health equity and meet eradication targets, holistic approaches that combine harm reduction, addiction treatment, mental health services, and HCV screening and therapy are crucial.\u003c/p\u003e \u003cp\u003eThe purpose of this review is to compile the most recent research on the reciprocal association between drug use and mental health conditions and HCV. It assesses treatment results in integrated care settings, investigates the ways in which different illnesses interact, and pinpoints knowledge and practice gaps. We want to influence therapeutic interventions, public health policy, and future research paths in line with the worldwide HCV elimination goals by clarifying the interdependencies between viral infections and mental health in this vulnerable population.\u003c/p\u003e"},{"header":"2.0 METHODS","content":"\u003cdiv id=\"Sec3\" class=\"Section2\"\u003e \u003ch2\u003e2.1 Design\u003c/h2\u003e \u003cp\u003eThis study employed a narrative literature review approach to examine the bidirectional relationship between mental health disorders and hepatitis C virus (HCV) infection among people who use drugs (PWUD). The review aimed to identify, summarize, and interpret existing peer-reviewed evidence on prevalence, risk behaviors, treatment adherence, integrated care models, and psychosocial factors influencing both conditions.\u003c/p\u003e \u003c/div\u003e \u003cdiv id=\"Sec4\" class=\"Section2\"\u003e \u003ch2\u003e2.2 Search Strategy\u003c/h2\u003e \u003cp\u003eA structured literature search was conducted across PubMed, PsycINFO, Scopus, and Google Scholar to examine the relationships between mental health disorders, substance use, and hepatitis C virus (HCV) among people who use drugs (PWUD). Key search combinations included \u0026ldquo;mental health and hepatitis C,\u0026rdquo; \u0026ldquo;mental health disorders and substance use,\u0026rdquo; \u0026ldquo;substance use and hepatitis C,\u0026rdquo; and \u0026ldquo;co-occurring disorders.\u0026rdquo; Initial searches yielded approximately 16,200, 16,700, 17,800, and 915 articles, respectively, prior to screening as seen in Fig.\u0026nbsp;\u003cspan refid=\"Fig1\" class=\"InternalRef\"\u003e1\u003c/span\u003e.\u003c/p\u003e \u003cp\u003e \u003c/p\u003e \u003c/div\u003e \u003cdiv id=\"Sec5\" class=\"Section2\"\u003e \u003ch2\u003e2.3 Inclusion and Exclusion Criteria\u003c/h2\u003e \u003cp\u003eTo be included in the review, studies had to meet the following criteria:\u003c/p\u003e \u003cp\u003e \u003cul\u003e \u003cli\u003e \u003cp\u003ePublished in English between 2010 and 2025.\u003c/p\u003e \u003c/li\u003e \u003cli\u003e \u003cp\u003ePeer-reviewed articles examining mental health and HCV in the context of drug use.\u003c/p\u003e \u003c/li\u003e \u003cli\u003e \u003cp\u003eFocus on adult populations (18\u0026thinsp;+\u0026thinsp;years).\u003c/p\u003e \u003c/li\u003e \u003cli\u003e \u003cp\u003eInclude quantitative, qualitative, or mixed methods designs.\u003c/p\u003e \u003c/li\u003e \u003c/ul\u003e \u003c/p\u003e \u003cp\u003eExclusion criteria included:\u003c/p\u003e \u003cp\u003e \u003cul\u003e \u003cli\u003e \u003cp\u003eStudies focusing exclusively on non-drug-using populations.\u003c/p\u003e \u003c/li\u003e \u003cli\u003e \u003cp\u003eEditorials, commentaries, or studies lacking empirical data.\u003c/p\u003e \u003c/li\u003e \u003c/ul\u003e \u003c/p\u003e \u003c/div\u003e \u003cdiv id=\"Sec6\" class=\"Section2\"\u003e \u003ch2\u003e2.4 Selection and Data Extraction\u003c/h2\u003e \u003cp\u003eIn order to determine relevance, two researchers independently assessed the first search results by title and abstract. All publications that satisfied the first inclusion criteria were then evaluated in full by both reviewers. A third reviewer was on hand to offer arbitration in the event of a disagreement; however, no contradictory evaluations emerged during the screening process, and all choices were agreed upon.\u003c/p\u003e \u003cp\u003eA standardized template was used for data extraction in order to methodically record data on research type, sample characteristics, treatment outcomes, documented impediments to integrated care, and the prevalence of HCV and mental health. A thematic synthesis was conducted after extraction in order to identify important gaps in the body of current research, summarize findings, and extract key trends.\u003c/p\u003e \u003c/div\u003e \u003cdiv id=\"Sec7\" class=\"Section2\"\u003e \u003ch2\u003e2.5 Ethical Considerations\u003c/h2\u003e \u003cp\u003eAs this review utilized publicly available data from previously published studies, no ethical approval was required.\u003c/p\u003e \u003c/div\u003e"},{"header":"3.0 RESULTS","content":"\u003cp\u003eAn initial pool of 51,615 papers was found through a methodical examination of electronic databases (PubMed, PsycINFO, Scopus, Google Scholar) using specific keywords relating to substance use, mental health, and hepatitis C. 127 articles were kept for full-text review after titles and abstracts were screened for relevancy. 39 studies were found to be qualified for inclusion in this narrative review after the inclusion and exclusion criteria (such as English language, publication between 2010 and 2025, and emphasis on adult PWUD) were applied. \u0026nbsp;Table 1 shows a summary of the findings of papers in this narrative review. The findings from the reviewed literature reveal a strong bidirectional association between mental health disorders and hepatitis C virus (HCV) infection among people who use drugs (PWUD). Three central themes emerged: (1) the impact of mental health conditions on HCV risk behaviors and treatment adherence, (2) the effects of chronic HCV infection on psychological well-being, and (3) the outcomes of integrated treatment approaches for co-occurring conditions.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003e3.1\u003c/strong\u003e\u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp;\u0026nbsp;\u003cstrong\u003eMental Health Disorders and Increased Risk of HCV\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eNumerous studies have reported that individuals with mental health disorders, particularly depression, anxiety, bipolar disorder, and post-traumatic stress disorder (PTSD), are at significantly higher risk for engaging in behaviors that facilitate HCV transmission. These behaviors include sharing needles, cookers, and inhalation paraphernalia (Connery et al., 2020; Mahoney et al., 2024). Among individuals with serious mental illness (SMI), HCV prevalence was found to be approximately 8%, with rates up to 11 times higher than in the general population (Braude et al., 2021). Mental health conditions were also linked to poor engagement in harm reduction programs and inconsistent use of sterile equipment.\u003c/p\u003e\n\u003cp\u003eRoncero et al. (2023) emphasized the prevalence of HCV infection in patients with chronic mental disorders, noting that dual disorders (co-occurring substance use and mental health issues) significantly exacerbate the risk. Their findings highlight the importance of addressing both mental health and substance use in treatment settings to reduce HCV transmission rates effectively. Specifically, the study found that patients with both mental health disorders and substance use issues exhibited higher rates of risky behaviors, such as sharing syringes and other paraphernalia, which directly contribute to the spread of HCV.\u003c/p\u003e\n\u003cp\u003eIn a rural New Mexico cohort, Gupta et al. (2022) identified a strong association between co-occurring mental health problems and HCV status among young people who inject drugs (PWID). Their research indicated that PTSD had a significant impact on HCV infection rates, mediated by risky injection behaviors such as receptive syringe sharing (RSS). This underscores the need for targeted interventions that integrate mental health services into harm reduction strategies. The study also highlighted that young PWID with a history of trauma were more likely to engage in risky injection practices, amplifying their vulnerability to HCV infection.\u003c/p\u003e\n\u003cp\u003eAas et al. (2024) further explored the effects of integrated HCV treatment on psychological distress in people with substance use disorders. Their study found that improving access to mental health care and reducing psychological distress could potentially mitigate the risk of HCV transmission among vulnerable populations. The integration of mental health services into HCV treatment not only addresses the psychological needs of patients but also encourages better adherence to treatment protocols and harm reduction practices.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003e3.2\u003c/strong\u003e\u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp;\u0026nbsp;\u003cstrong\u003eThe effects of chronic HCV infection on psychological well-being\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eHCV infection can adversely impact mental health through both biological and psychological mechanisms. Chronic infection has been associated with neuroinflammatory processes that contribute significantly to the development of depressive and anxiety symptoms, highlighting the complex interplay between physical and mental health (Guo et al., 2023).\u0026nbsp;Chronic viral hepatitis, including HCV, is associated with a range of neuropsychiatric manifestations such as depression, anxiety, cognitive impairment, and fatigue, driven by neuroinflammatory and metabolic mechanisms (Polukchi et al., 2023). The stress of living with a stigmatized, incurable illness often results in social isolation, hopelessness, and worsening psychiatric conditions, with these effects being particularly pronounced among individuals who already struggle with pre-existing mental health disorders or lack stable social support systems (Ahmed et al., 2023; NIMH, 2025).\u003c/p\u003e\n\u003cp\u003eResearch shows that HCV leads to neuroinflammation, disrupting neurotransmitter systems crucial for mood regulation. This disruption can exacerbate existing mood disorders, such as depression and anxiety, thus creating a cycle of worsening health (Okobi et al., 2024). Moreover, the psychological burden associated with HCV can amplify feelings of shame and social isolation, leading to a reluctance to seek necessary medical help or engage in supportive communities. Stigmatization surrounding HCV often deters individuals from pursuing treatment, which can further exacerbate their mental health challenges (Flisiak et al., 2025).\u003c/p\u003e\n\u003cp\u003eIn addition to these psychological impacts, the presence of mental health disorders complicates adherence to HCV treatment regimens. Individuals facing co-occurring conditions often experience barriers such as cognitive impairment, emotional distress, and a lack of motivation, all of which hinder their ability to comply with treatment protocols effectively (Taye, 2021). The cumulative effect of these challenges underscores the urgent need for integrated care models that address both HCV and mental health simultaneously. Such models can facilitate better health outcomes by ensuring that individuals receive comprehensive care tailored to their unique needs.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003e3.3\u003c/strong\u003e\u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp;\u0026nbsp;\u003cstrong\u003eOutcomes of integrated treatment approaches for co-occurring conditions.\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eEvidence from integrated care models suggests that addressing mental health and HCV concurrently leads to improved treatment adherence, higher sustained virologic response, and improved mental health outcomes (Mahoney et al., 2024).Studies highlighted those patients receiving coordinated care where psychiatric support is embedded within HCV treatment programs demonstrated better medication adherence, higher rates of sustained virologic response (SVR), and improved mental health outcomes (Mahoney et al., 2024). However, many of these models remain underutilized due to structural barriers, provider shortages, and stigma associated with both conditions.\u003c/p\u003e\n\u003cp\u003eFor instance, a multicenter randomized controlled trial (INTRO-HCV) demonstrated that integrated treatment for hepatitis C among people who inject drugs (PWID) resulted in a notably higher rate of sustained virologic response (SVR), with 98% of participants initiating treatment compared to 77% in standard care (Fadnes et al., 2021). This study underscores the effectiveness of integrated care models that combine HCV treatment with support for substance use and mental health conditions.\u003c/p\u003e\n\u003cp\u003eFurther supporting this, a harm reduction-focused primary care program in New York City found that housing instability and Medicaid insurance were key predictors affecting treatment completion and follow-up for SVR testing (Ziff et al., 2021). This indicates that social determinants significantly influence treatment outcomes, thereby highlighting the necessity of integrated models that address these factors alongside medical treatment.\u003c/p\u003e\n\u003cp\u003eMoreover, recent literature reviews indicate that patients with severe mental illness who are co-infected with HCV benefit from newer pangenotypic direct-acting antivirals, which have shown improved treatment adherence and outcomes (Gutiérrez-Rojas et al., 2023). Integrating psychiatric care into HCV treatment not only enhances medication adherence but also improves mental health outcomes, emphasizing the holistic benefits of such approaches.\u003c/p\u003e\n\u003cp\u003eDespite these positive findings, many integrated treatment models remain underutilized due to structural barriers, provider shortages, and the stigma associated with both conditions (Adler et al., 2023).\u003c/p\u003e"},{"header":"4.0 DISCUSSION","content":"\u003cp\u003eThis literature review highlights the complex and bidirectional relationship between mental health disorders and hepatitis C virus (HCV) infection among people who use drugs (PWUD). The findings underscore that untreated mental health conditions significantly increase the risk of HCV acquisition, while chronic HCV infection can, in turn, exacerbate psychological distress through both biological mechanisms and psychosocial challenges. These findings carry important implications for clinical practice, public health programming, and policy development.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003e4.1\u003c/strong\u003e\u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp;\u0026nbsp;\u003cstrong\u003e\u0026nbsp;Mental Health Disorders and Increased Risk of HCV\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eRepeating Connery et al. (2020) and Hashim et al. (2021), our findings attest that mental illness conditions such as depression, anxiety, bipolar disorder, and post-traumatic stress disorder (PTSD) are exceedingly common among drug users and play a major role in risky behaviors that spread HCV, including needle, cooker, and inhalation equipment sharing. Roncero et al. (2023) also add to this point by noting that dual disorders (the co-occurrence of substance use and mental illness) heighten these risks and advocate for treating both in clinical environments.\u003c/p\u003e\n\u003cp\u003eThe HCV prevalence among people with serious mental illness (SMI) continues to be a significant issue, with prevalence rates around 8%, which is up to 11 times greater than that of the general population. This is consistent with Braude et al. (2021), who report that mental illness is linked to poor attendance at harm reduction services and irregular use of sterile equipment, making HCV control more difficult. Gupta et al. (2022) further state that, in young PWID in rural New Mexico, PTSD has a significant effect on HCV infection through unsafe injection practices such as receptive syringe sharing (RSS), highlighting the importance of incorporating mental health services into harm reduction interventions.\u003c/p\u003e\n\u003cp\u003eBeyond behavior, this review identifies the psychiatric and neurological effects of HCV infection, exacerbating underlying mental illness and resulting in cognitive impairment and increased anxiety. Overall health and treatment adherence are challenged by this reciprocal connection. \u0026nbsp;As Rifai \u0026amp; Rosenstein (2005) note, stigma around mental illness and HCV both deter people from getting therapy, which feeds a vicious cycle of poor health.\u003c/p\u003e\n\u003cp\u003eAas et al. (2024) argue that while integrated HCV treatment is beneficial, it may not significantly reduce psychological suffering in patients with substance use disorders, requiring the use of specific mental health interventions in addition to HCV treatment. \u0026nbsp; However, as Fuentes et al. (2022) note, HCV screening at mental health facilities is an intriguing intervention opportunity that could improve treatment and results for individuals with mental disorders. \u0026nbsp;Recent Mendelian randomization studies, like Fu et al. (2024), provide evidence that mental illnesses, specifically bipolar disorder and schizophrenia, may raise the incidence of chronic HCV, indicating a complicated link that needs further investigation.\u003c/p\u003e\n\u003cp\u003eModels like the Clubhouse model need to take social determinants of health (SDoH) into account to better understand the factors influencing mental health and HCV control. \u0026nbsp; The need for complex interventions as shown by Kinney et al. (2022) advocates culturally relevant interventions that profoundly penetrate risk populations. \u0026nbsp; \u0026nbsp;When HCV co-occurs with co-occurring substance use disorders or mental disorders, combined care models have shown promise for improving patient outcomes and treatment uptake.\u003c/p\u003e\n\u003cp\u003eTreatment compliance and general health are further complicated by this reciprocal interaction. \u0026nbsp;Patients are discouraged from seeking treatment due to the stigma associated with mental health illnesses and HCV, which perpetuates the vicious cycle of poor health. \u0026nbsp;Rifai and Rosenstein (2005). \u0026nbsp;It is advised to use prescribed mental health interventions in addition to HCV therapy since, despite the potential benefits of an integrated model, an integrated treatment will not significantly relieve the mental health burden of the affected group (Aas et al., 2024). One novel intervention strategy that potentially enhance the treatment and results for individuals with mental illness is HCV screening in mental health settings (Fuentes et al. 2022). To understand the factors affecting mental health and HCV management in a better way, the Clubhouse model and others must also focus on social determinants of health (SDoH). Cultural interventions that investigate the risk communities call attention to the criticality of complex interventions Kinney et al. (2022).\u0026nbsp;\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003e4.2\u003c/strong\u003e\u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp;\u0026nbsp;\u003cstrong\u003e\u0026nbsp;Psychological Burden of Chronic HCV\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eThe impact of chronic HCV on mental health is very substantial. \u0026nbsp; According to recent studies, anxiety and sadness may result from neuroinflammatory changes associated with HCV (Guo et al., 2023). \u0026nbsp; Patients often experience severe psychological distress, which can show up as physical symptoms, fatigue, and cognitive impairment (Rashid et al., 2025). \u0026nbsp; \u0026nbsp;Ahmed et al. (2023) claims that the stigma surrounding HCV illness exacerbates social exclusion and denigration, which intensifies emotional distress and starts a vicious cycle in which psychological symptoms lower treatment compliance. The impact of chronic HCV on mental health is very substantial. \u0026nbsp;Anxiety and depression may result from neuroinflammatory changes associated with HCV (Guo et al., 2023). \u0026nbsp; According to Rashid et al. (2025), patients frequently experience severe psychological pain, which can manifest as physical symptoms, fatigue, and cognitive impairment. \u0026nbsp; Emotional anguish is made worse by stigma associated with HCV, which increases social exclusion and humiliation. \u0026nbsp;Because psychological symptoms lead to lower treatment adherence, this discomfort creates a vicious cycle (Ahmed et al., 2023).\u003c/p\u003e\n\u003cp\u003eAccording to investigations, more than half of patients had low life satisfaction scores, suggesting that CHC patients typically experience lower levels of life satisfaction (Sierpińska, 2023). \u0026nbsp;Additionally, among CHC patients, socioeconomic vulnerability attributes including homelessness and minority status are linked to elevated prescription opioid usage, which worsens their psychological distress (Butt et al., 2021). \u0026nbsp; The very existence of this association emphasizes the relevance of incorporating mental and physical health into treatment plans.\u003c/p\u003e\n\u003cp\u003eNotably, health-related quality of life and psychological well-being have been seen to improve after HCV elimination using direct-acting antiviral drugs (Bertino et al., 2021). This indicates that effective treatment can go a long way in relieving some of the mental health loads borne by patients. Additionally, the mediating effect of hope has been found to play a key role in promoting the quality of life of hepatitis patients, which implies that the promotion of positive emotional states can buffer psychological distress (Bano et al., 2024).\u003c/p\u003e\n\u003cp\u003eThe relationship between chronic HCV and mental health is bidirectional and complex. To improve overall outcomes for people with chronic hepatitis C, mental health services must be integrated into hepatitis care, social support must be encouraged, and psychological symptoms must be treated.\u003c/p\u003e\n\u003cp\u003e\u0026nbsp;Our findings corroborate the recent study conducted by Guo et al. (2023), demonstrating that neuroinflammatory processes associated with chronic HCV infection play a role in the pathophysiology of depressive and anxiety symptoms. These findings align with Rashid et al. (2025), who explain that changes in neuroinflammation can lead to cognitive impairment, chronic fatigue, and somatic symptoms, which additionally complicate the mental health scenario in such patients.\u003c/p\u003e\n\u003cp\u003eThe psychological burden of HCV infection often exacerbates social disengagement and shame, making it difficult for people to get much-needed medical care. \u0026nbsp; This stigma is reinforced by Ahmed et al. (2023), who point out that the stress of having a stigmatized, incurable ailment can result in social isolation and poverty, particularly for people who are already dealing with a mental problem. \u0026nbsp; Taye's (2021) claim that co-occurring disorders frequently provide obstacles to successful treatment adherence is supported by the self-reinforcing loop that these psychological issues produce, which may significantly reduce treatment adherence.\u003c/p\u003e\n\u003cp\u003eThe idea that co-morbid conditions frequently create obstacles to efficient treatment adherence is supported by the self-reinforcing nature of the psychological problems that arise, which may drastically lower treatment adherence. \u0026nbsp;(Taye, 2021). Furthermore, our data suggest that individuals with chronic hepatitis C also frequently have reduced life satisfaction, a finding that Sierpińska (2023) supported, as more than half of patients had low satisfaction levels. \u0026nbsp;Butt et al. (2021) also finds a link between social vulnerability characteristics, homelessness, minority status and increased psychological challenges, supporting the need for dual treatment approaches that address mental and physical health.\u003c/p\u003e\n\u003cp\u003eInterestingly, health-related quality of life and psychological well-being improvements after HCV elimination using direct-acting antiviral drugs have been reported (Bertino et al., 2021). The belief is that patients' mental health burdens may be mitigated with effective therapy. \u0026nbsp;Our review demonstrates that fostering pleasant emotional states, as mentioned by Bano et al. (2024), can be crucial in alleviating psychological discomfort. This suggests that mental health remedies should be included in hepatitis treatment.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003e4.3\u003c/strong\u003e\u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp;\u0026nbsp;\u003cstrong\u003eIntegrated Models of Care\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eWhen it comes to treating serious mental illness, substance use disorders, and the hepatitis C virus (HCV), integrated care models have demonstrated great promise. Coordinated mental health and HCV services have been linked to improved psychological outcomes, increased treatment completion rates, and enhanced patient involvement (Mahoney et al., 2024). For example, Braude et al. (2023) analyzed the care cascade at a tertiary health facility and demonstrated the efficacy of a pilot \"identify and treat\" method for HCV among people with severe mental illness. According to their findings, specific strategies may improve treatment adherence in this susceptible group.\u003c/p\u003e\n\u003cp\u003eAdditionally, patients who inject drugs have found success with patient-centered models of care, proving that tailored treatment plans can improve health outcomes (Litwin et al., 2022). These methods improve patients' adherence to treatment plans by focusing on their needs and situations. Nevertheless, integrated care models are still not widely used, especially in settings with limited resources, despite the encouraging outcomes. Scalability and sustainability are restricted by structural obstacles, such as provider shortages, disjointed health systems, and enduring stigma (Schwarz et al., 2022). Improving care access and outcomes for people with HCV and co-occurring illnesses depends on addressing these issues.\u0026nbsp;Integrated approaches are particularly critical in high-risk settings such as the criminal justice system, where the co-occurrence of opioid use disorder, mental illness, and infectious diseases like HCV is common and continuity of care is frequently disrupted (Winetsky et al., 2020).\u003c/p\u003e\n\u003cp\u003eAlthough integrated care models provide a way ahead for controlling HCV and associated comorbidities, more work is required to get over current challenges and guarantee that these models are broadly accepted and successfully put into practice. The results of integrated care models demonstrate the advantages of treating hepatitis C virus (HCV) and mental health at the same time, improving both conditions. \u0026nbsp;Our results are consistent with those of Mahoney et al. (2024), who indicate improved mental health outcomes, increased rates of sustained virologic response (SVR), and greater drug adherence among patients getting integrated care with embedded psychological support. \u0026nbsp;This lends credence to the idea that integrated strategies might greatly improve HCV treatment efficacy.\u003c/p\u003e\n\u003cp\u003eFor example, integrated therapy for hepatitis C among individuals who inject drugs (PWID) led to a much higher SVR rate; 98% of patients started treatment compared to 77% in standard care, according to the multicenter randomized controlled study (INTRO-HCV) (Fadnes et al., 2021). This result is consistent with the findings of Braude et al. (2023), who demonstrated the effectiveness of a pilot \"identify and treat\" approach in a tertiary health care for patients with severe mental illness. These focused strategies imply that integrated care can successfully increase treatment uptake in susceptible groups, highlighting the advantages of linked HCV and mental health services.\u003c/p\u003e\n\u003cp\u003eFurthermore, our analysis highlights how important social variables are in determining treatment outcomes. Housing instability and Medicaid insurance were found to be important determinants of treatment completion and SVR test follow-up in the harm reduction-focused program in New York City (Ziff et al., 2021). This is consistent with the findings of Schwarz et al. (2022), who point out that structural obstacles, like a lack of providers and disjointed health systems, restrict the scalability of integrated care models, especially in environments with limited resources. Furthermore, novel pangenotypic direct-acting antivirals have been shown to increase treatment adherence and outcomes for patients with severe mental illness co-infected with HCV (Gutiérrez-Rojas et al., 2023).\u003c/p\u003e\n\u003cp\u003eThis highlights the significance of incorporating psychiatric care into HCV treatment since it improves general mental health and increases medication adherence, highlighting a patient-centered approach. Many integrated care methods are still underutilized despite the encouraging results regarding them because of the ongoing stigma attached to both HCV and mental health issues (Adler et al., 2023). This stigma might discourage people from getting help and participating in supportive care, underscoring the critical need for all-encompassing solutions to these problems.\u003c/p\u003e\n\u003cp\u003eThe management of the overlapping problems of substance use disorders, mental health diseases, and the hepatitis C virus (HCV) has significantly improved thanks to integrated care methods. Coordinated mental health and HCV care have been associated with better psychological outcomes, increased treatment completion rates, and increased patient participation (Mahoney et al., 2024). The efficacy of a pilot \"identify and treat\" strategy for HCV in individuals with severe mental illness was highlighted by a care cascade analysis at a tertiary health service (Braude et al., 2023). These findings suggest that targeted treatments can increase this high-risk population's adherence to treatment. Customized approaches can result in better health outcomes, as evidenced by the effectiveness of patient-centered care models for injecting drug users (Litwin et al., 2022).\u003c/p\u003e\n\u003cp\u003eEven with these developments, integrated care models remain underutilized, particularly in settings with limited resources. Their growth and long-term survival are hampered by significant challenges like a lack of workers, disjointed healthcare systems, and enduring stigma (Schwarz et al., 2022). New research supports the benefits of treating HCV and mental health issues at the same time, leading to synergistic gains in both areas. Our findings are consistent with those of Mahoney et al. (2024), who discovered improved mental health indicators, higher sustained virologic response (SVR) rates, and better drug adherence among patients getting coordinated care with integrated psychiatric assistance. This highlights how coordinated approaches can significantly improve the effectiveness of HCV treatment.\u003c/p\u003e\n\u003cp\u003eFor example, integrated HCV treatment for individuals who inject drugs (PWID) obtained an SVR rate with 98% treatment initiation compared to 77% in standard care, according to the multicenter INTRO-HCV randomized controlled study (Fadnes et al., 2021). This corroborates the findings of Braude et al. (2023), whose trial \"identify and treat\" program in a tertiary setting effectively raised uptake among those with severe mental illness. These focused initiatives confirm that integrated care can increase participation in vulnerable populations, enhancing the benefits of coordinated HCV and mental health services. Our analysis also emphasizes how important social variables are to the effectiveness of treatment. Housing instability and Medicaid coverage were identified by a harm reduction program in New York City as key determinants of treatment completion and SVR follow-up (Ziff et al., 2021).\u003c/p\u003e\n\u003cp\u003eThese observations are consistent with those of Schwarz et al. (2022), who noted structural obstacles to scaling integrated models in low-resource situations, including as provider shortages and disjointed systems. According to recent research, current pangenotypic direct-acting antivirals improve adherence and overall results in patients with severe mental illness and HCV co-infection (Gutiérrez-Rojas et al., 2023).\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003e4.4\u003c/strong\u003e\u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp;\u0026nbsp;\u003cstrong\u003eResearch Gaps and Limitations\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eAlthough the reviewed literature provides valuable insights, several gaps remain:\u003c/p\u003e\n\u003cp\u003eI.\u0026nbsp; \u0026nbsp; \u0026nbsp;\u003cu\u003eLack of longitudinal evidence\u003c/u\u003e: Most studies were cross-sectional, limiting understanding of causality and temporal trends.\u003c/p\u003e\n\u003cp\u003eII.\u0026nbsp; \u0026nbsp;\u003cu\u003eLimited population diversity\u003c/u\u003e: Research rarely disaggregated findings by gender, age, race/ethnicity, or socioeconomic status.\u003c/p\u003e\n\u003cp\u003eIII.\u0026nbsp;\u0026nbsp;\u003cu\u003eUnderrepresentation of qualitative perspectives\u003c/u\u003e: The voices of individuals living with co-occurring disorders are largely absent from existing research.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eIV.\u0026nbsp;\u003c/strong\u003e\u003cu\u003eVariable quality of evidence\u003c/u\u003e: Some studies lacked standardized measurement tools or had small sample sizes, limiting generalizability.\u003c/p\u003e"},{"header":"5.0 CONCLUSION","content":"\u003cp\u003eThe evidence reviewed in this study reinforces the urgent need to address the bidirectional relationship between mental health disorders and hepatitis C virus (HCV) infection among people who use drugs (PWUD). Mental health challenges significantly elevate the risk of HCV transmission through risky behaviors and poor adherence to treatment, while chronic HCV infection contributes to psychological distress through biological and psychosocial mechanisms.\u003c/p\u003e \u003cp\u003eIntegrated treatment approaches that address both conditions simultaneously offer a promising path forward. However, their implementation remains limited due to structural barriers, under-resourcing, and stigma. Bridging this gap will require coordinated efforts across disciplines psychiatry, infectious diseases, public health, and substance use treatment. Future research should prioritize longitudinal and population-specific studies, as well as mixed-methods and qualitative approaches that center on the experiences of those most affected. Ultimately, advancing integrated care models and evidence-based policy interventions will be critical to improving health outcomes for this vulnerable population and achieving global HCV elimination goals.\u003c/p\u003e"},{"header":"Declarations","content":"\u003cp\u003e\u003cstrong\u003eAvailability of Data and Materials\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eConsent to participate\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eNot applicable\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eConsent to publish\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eNot applicable. This study does not contain any individual person\u0026rsquo;s data in any form.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eEthics statement\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eAs this review utilized publicly available data from previously published studies, no ethical approval was required.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eClinical Trial Number\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eNot applicable\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eFunding Declaration\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eThe authors declare that this research received no funding\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eDeclaration of Interest Statement\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003e\u0026nbsp;The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eEthical Accordance\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eThis narrative review solely relies on the abundance of already published, publicly available research, so no fresh primary data nor direct human participation were gathered. As a result, official ethical approval was not obtained. However, we conducted this synthesis with a thorough dedication to academic integrity, paying close attention to the confidentiality guidelines and ethical clearances that the original researchers had already set. To ensure that our study is primarily in its commitment to ethical scholarship even though it is secondary in nature, our work seeks to acknowledge what they have accomplished through transparent acknowledgment.\u003c/p\u003e"},{"header":"References","content":"\u003col\u003e\n\u003cli\u003eAhmed, M., Cerda, I., \u0026amp; Maloof, M. (2023). Breaking the vicious cycle: The interplay between loneliness, metabolic illness, and mental health. \u003cem\u003eFrontiers in Psychiatry, 14\u003c/em\u003e, 1134865. https://doi.org/10.3389/fpsyt.2023.1134865 \u003c/li\u003e\n\u003cli\u003eBaingana, F., al\u0026rsquo;Absi, M., Becker, A. E., \u0026amp; Pringle, B. (2015). Global research challenges and opportunities for mental health and substance-use disorders. \u003cem\u003eNature, 527\u003c/em\u003e(7578), S172\u0026ndash;S177. https://doi.org/10.1038/nature16032 \u003c/li\u003e\n\u003cli\u003eBraude, M. R., Phan, T., Dev, A., \u0026amp; Sievert, W. (2021). Determinants of hepatitis C virus prevalence in people with serious mental illness: A systematic review and meta-analysis. \u003cem\u003eThe Journal of Clinical Psychiatry, 83\u003c/em\u003e(1), 21r14079. https://doi.org/10.4088/JCP.21r14079 \u003c/li\u003e\n\u003cli\u003eCenters for Disease Control and Prevention. (2024, June 10). \u003cem\u003eGlobal viral hepatitis\u003c/em\u003e. https://www.cdc.gov/hepatitis/global/index.html \u003c/li\u003e\n\u003cli\u003eConnery, H. S., McHugh, R. K., Reilly, M., Shin, S., \u0026amp; Greenfield, S. F. (2020). Substance use disorders in global mental health delivery: Epidemiology, treatment gap, and implementation of evidence-based treatments. \u003cem\u003eHarvard Review of Psychiatry, 28\u003c/em\u003e(5), 316\u0026ndash;327. https://doi.org/10.1097/HRP.0000000000000271\u003c/li\u003e\n\u003cli\u003eGuo, B., Zhang, M., Hao, W., Wang, Y., Zhang, T., \u0026amp; Liu, C. (2023). Neuroinflammation mechanisms of neuromodulation therapies for anxiety and depression. \u003cem\u003eTranslational Psychiatry, 13\u003c/em\u003e(1), 5. https://doi.org/10.1038/s41398-022-02297-y \u003c/li\u003e\n\u003cli\u003eFaccioli, J., Nardelli, S., Gioia, S., Riggio, O., \u0026amp; Ridola, L. (2021). Neurological and psychiatric effects of hepatitis C virus infection. \u003cem\u003eWorld Journal of Gastroenterology\u003c/em\u003e, \u003cem\u003e27\u003c/em\u003e(29), 4846\u0026ndash;4861. https://doi.org/10.3748/wjg.v27.i29.4846\u003c/li\u003e\n\u003cli\u003eHashim, A., Macken, L., Jones, A., et al. (2021). Community-based assessment and treatment of hepatitis C virus-related liver disease, injecting drug and alcohol use amongst people who are homeless: A systematic review and meta-analysis. \u003cem\u003eInternational Journal of Drug Policy, 96\u003c/em\u003e, 103342. https://doi.org/10.1016/j.drugpo.2021.103342 \u003c/li\u003e\n\u003cli\u003eMahoney, B. J., Morford, K. L., Biegacki, E. T., \u0026amp; Tetrault, J. M. (2024). Hepatitis C virus and integrated care for substance use disorders. \u003cem\u003eClinical Liver Disease (Hoboken), 23\u003c/em\u003e(1), e0241. https://doi.org/10.1097/CLD.0000000000000241 \u003c/li\u003e\n\u003cli\u003eNational Institute on Drug Abuse. (2020). \u003cem\u003eCommon comorbidities with substance use disorders research report\u003c/em\u003e. https://www.drugabuse.gov/publications/research-reports/common-comorbidities-with-substance-use-disorders/part-1-connection-between-substance-use-disorders-mental-illness \u003c/li\u003e\n\u003cli\u003eUnderstanding the link between chronic disease and depression\u0026mdash;National institute of Mental Health (NIMH). (n.d.). Retrieved November 11, 2025, from https://www.nimh.nih.gov/health/publications/chronic-illness-mental-health\u003c/li\u003e\n\u003cli\u003eHepatitis c. (n.d.). Retrieved November 11, 2025, from https://www.who.int/news-room/fact-sheets/detail/hepatitis-c\u003c/li\u003e\n\u003cli\u003eBano, M., Hussain, S., Rida Mehmood, H., Arshad, O., \u0026amp; Sher, A. (2024). Psychological distress and quality of life in hepatitis patients: The mediating role of hope. \u003cem\u003eJournal of Asian Development Studies\u003c/em\u003e, \u003cem\u003e13\u003c/em\u003e(3), 1092\u0026ndash;1100. https://doi.org/10.62345/jads.2024.13.3.89\u003c/li\u003e\n\u003cli\u003eBraude, M., Phan, T., Con, D., Woolley, I., Sundram, S., Clarke, D., Dev, A., \u0026amp; Sievert, W. (2023). Hepatitis C virus in people with serious mental illness: An analysis of the care cascade at a tertiary health service with a pilot \u0026lsquo;identify and treat\u0026rsquo; strategy. \u003cem\u003eInternal Medicine Journal\u003c/em\u003e, \u003cem\u003e53\u003c/em\u003e(5), 700\u0026ndash;708. https://doi.org/10.1111/imj.15604\u003c/li\u003e\n\u003cli\u003eButt, A. A., Yan, P., Kapadia, S., Abou-Samra, A.-B., Janjua, N. Z., \u0026amp; Ibrahim, S. (2021). Social vulnerability in persons with chronic hepatitis C virus infection is associated with a higher risk of prescription opioid use. \u003cem\u003eScientific Reports\u003c/em\u003e, \u003cem\u003e11\u003c/em\u003e(1), 5883. https://doi.org/10.1038/s41598-021-85283-6\u003c/li\u003e\n\u003cli\u003eFu, H., Jiang, S., Song, S., Zhang, C., \u0026amp; Xie, Q. (2024). Causal associations between chronic viral hepatitis and psychiatric disorders: A Mendelian randomization study. \u003cem\u003eFrontiers in Psychiatry\u003c/em\u003e, \u003cem\u003e15\u003c/em\u003e, 1359080. https://doi.org/10.3389/fpsyt.2024.1359080\u003c/li\u003e\n\u003cli\u003eKinney, A. R., Bahraini, N., Donovan, M. L., \u0026amp; Brenner, L. A. (2022). Characterizing social determinants of health in research regarding the clubhouse model for individuals with mental health conditions. \u003cem\u003eCurrent Treatment Options in Psychiatry\u003c/em\u003e, \u003cem\u003e9\u003c/em\u003e(4), 376\u0026ndash;405. https://doi.org/10.1007/s40501-022-00274-2\u003c/li\u003e\n\u003cli\u003eLitwin, A. H., Lum, P. J., Taylor, L. E., Mehta, S. H., Tsui, J. I., Feinberg, J., Kim, A. Y., Norton, B. L., Heo, M., Arnsten, J., Meissner, P., Karasz, A., Mckee, M. D., Ward, J. W., Johnson, N., Pericot-Valverde, I., Agyemang, L., Stein, E. S., Thomas, A., \u0026hellip; Page, K. (2022). Patient-centred models of hepatitis C treatment for people who inject drugs: A multicentre, pragmatic randomised trial. \u003cem\u003eThe Lancet Gastroenterology \u0026amp; Hepatology\u003c/em\u003e, 7(12), 1112\u0026ndash;1127. https://doi.org/10.1016/S2468-1253(22)00275-8\u003c/li\u003e\n\u003cli\u003eMahoney, B. J., Morford, K. L., Biegacki, E. T., \u0026amp; Tetrault, J. M. (2024). Hepatitis C virus and integrated care for substance use disorders. \u003cem\u003eClinical Liver Disease,\u003c/em\u003e 23(1). https://doi.org/10.1097/CLD.0000000000000241\u003c/li\u003e\n\u003cli\u003eMarcellusi, A., Simonelli, C., Mennini, F. S., Kondili, L. A., \u0026amp; PITER Collaborating Group available at http://www.progettopiter.it. (2022). Economic consequences of anti-hcv treatment of patients diagnosed through screening in italy: A prospective modelling analysis. \u003cem\u003eApplied Health Economics and Health Policy\u003c/em\u003e, \u003cem\u003e20\u003c/em\u003e(1), 133\u0026ndash;143. https://doi.org/10.1007/s40258-021-00677-x\u003c/li\u003e\n\u003cli\u003ePolukchi, T. V., Abuova, G. N., \u0026amp; Slavko, Y. A. (2023). The neuropsychiatric aspect of chronic viral hepatitis. \u003cem\u003ePrague Medical Report\u003c/em\u003e, \u003cem\u003e124\u003c/em\u003e(2), 94\u0026ndash;107. https://doi.org/10.14712/23362936.2023.8\u003c/li\u003e\n\u003cli\u003eRashid, A. A., Rashid, A., Zahra, M., Aslam, N., Jameel, S., Awais, H. M., \u0026amp; Zaheer, H. (2025). Psychosomatic and psychological impact of hepatitis c: A cross-sectional study of depression, fibrosis, and somatic symptoms in treatment-naive and treatment-experienced patients who achieved sustained virologic response. \u003cem\u003eCureus\u003c/em\u003e. https://doi.org/10.7759/cureus.80104\u003c/li\u003e\n\u003cli\u003eRifai, M. A., \u0026amp; Rosenstein, D. L. (2005). Hepatitis C and psychiatry. \u003cem\u003eFocus\u003c/em\u003e, \u003cem\u003e3\u003c/em\u003e(2), 194\u0026ndash;202. https://doi.org/10.1176/foc.3.2.194\u003c/li\u003e\n\u003cli\u003eSchwarz, T., Horv\u0026aacute;th, I., Fenz, L., Schmutterer, I., Rosian-Schikuta, I., \u0026amp; M\u0026aring;rdh, O. (2022). Interventions to increase linkage to care and adherence to treatment for hepatitis C among people who inject drugs: A systematic review and practical considerations from an expert panel consultation. \u003cem\u003eInternational Journal of Drug Policy\u003c/em\u003e, \u003cem\u003e102\u003c/em\u003e, 103588. https://doi.org/10.1016/j.drugpo.2022.103588\u003c/li\u003e\n\u003cli\u003eSierpińska, L. E. (2023). Assessment of the level of life satisfaction and health behaviors among patients with chronic hepatitis c. \u003cem\u003eAmerican Journal of Health Behavior\u003c/em\u003e, \u003cem\u003e47\u003c/em\u003e(3), 595\u0026ndash;604. https://doi.org/10.5993/AJHB.47.3.17\u003c/li\u003e\n\u003cli\u003eSulkowski, M., Ionescu-Ittu, R., Macaulay, D., \u0026amp; Sanchez-Gonzalez, Y. (2020). The economic value of improved productivity from treatment of chronic hepatitis c virus infection: A retrospective analysis of earnings, work loss, and health insurance data. \u003cem\u003eAdvances in Therapy\u003c/em\u003e, \u003cem\u003e37\u003c/em\u003e(11), 4709\u0026ndash;4719. https://doi.org/10.1007/s12325-020-01492-x\u003c/li\u003e\n\u003cli\u003eYang, J., Qi, J.-L., Wang, X.-X., Li, X.-H., Jin, R., Liu, B.-Y., Liu, H.-X., \u0026amp; Rao, H.-Y. (2023a). The burden of hepatitis C virus in the world, China, India, and the United States from 1990 to 2019. \u003cem\u003eFrontiers in Public Health\u003c/em\u003e, 11, 1041201. https://doi.org/10.3389/fpubh.2023.1041201O \u003c/li\u003e\n\u003cli\u003eRoncero, C., Buch-Vicente, B., Mart\u0026iacute;n-S\u0026aacute;nchez, \u0026Aacute;. M., \u0026Aacute;lvarez-Navares, A. I., Andr\u0026eacute;s-Olivera, P., Gamonal-Limcaoco, S., Lozano-L\u0026oacute;pez, M. T., Aguilar, L., S\u0026aacute;nchez-Casado, F., \u0026amp; Garc\u0026iacute;a-Ull\u0026aacute;n, L. (2023). Prevalence of hepatitis C virus infection in patients with chronic mental disorders: The relevance of dual disorders. \u003cem\u003eGastroenterolog\u0026iacute;a y Hepatolog\u0026iacute;a (English Edition)\u003c/em\u003e, \u003cem\u003e46\u003c/em\u003e(3), 171\u0026ndash;177. https://doi.org/10.1016/j.gastre.2022.06.005\u003c/li\u003e\n\u003cli\u003eGupta, A., Shebl, F. M., Tong, Y., Wagner, K., Bassett, I. V., Page, K., \u0026amp; Winstanley, E. L. (2022). Association of co-occurring mental health problems with hepatitis C status among young people who inject drugs in rural New Mexico, 2016\u0026ndash;2018. \u003cem\u003eAddiction Science \u0026amp; Clinical Practice\u003c/em\u003e, \u003cem\u003e17\u003c/em\u003e(1), 58. https://doi.org/10.1186/s13722-022-00340-3\u003c/li\u003e\n\u003cli\u003eAas, C. F., Vold, J. H., Chalabianloo, F., L\u0026oslash;berg, E.-M., Lim, A. G., Vickerman, P., Johansson, K. A., \u0026amp; Fadnes, L. T. (2024). Effect of integrated hepatitis C virus treatment on psychological distress in people with substance use disorders. \u003cem\u003eScientific Reports\u003c/em\u003e, \u003cem\u003e14\u003c/em\u003e(1), 816. https://doi.org/10.1038/s41598-024-51336-9\u003c/li\u003e\n\u003cli\u003eOkobi, O. E., Ayo-Farai, O., Tran, M., Ibeneme, C., Ihezie, C. O., Ezie, O. B., \u0026amp; Adeakin-Dada, T. O. (2024). The impact of infectious diseases on psychiatric disorders: A systematic review. \u003cem\u003eCureus\u003c/em\u003e. https://doi.org/10.7759/cureus.66323\u003c/li\u003e\n\u003cli\u003eFlisiak, R., Rzymski, P., Flisiak-Jackiewicz, M., Brzdęk, M., \u0026amp; Zarębska-Michaluk, D. (2025). Treatment of chronic hepatitis C infection: Strategies to address poor therapy adherence. \u003cem\u003eExpert Review of Anti-Infective Therapy\u003c/em\u003e, \u003cem\u003e23\u003c/em\u003e(6), 379\u0026ndash;387. https://doi.org/10.1080/14787210.2025.2486353\u003c/li\u003e\n\u003cli\u003eTaye, B. W. (2021). \u003cem\u003eHepatitis C virus infection and tobacco smoking - joint health effects and implications for treatment of both: A systematic review\u003c/em\u003e. https://doi.org/10.1101/2021.10.12.21264923\u003c/li\u003e\n\u003cli\u003ePiekut, T., Hurła, M., Banaszek, N., Szejn, P., Dorszewska, J., Kozubski, W., \u0026amp; Prendecki, M. (2022). Infectious agents and Alzheimer\u0026rsquo;s disease. \u003cem\u003eJournal of Integrative Neuroscience\u003c/em\u003e, \u003cem\u003e21\u003c/em\u003e(2), 73. https://doi.org/10.31083/j.jin2102073\u003c/li\u003e\n\u003cli\u003eWinetsky, D., Fox, A., Nijhawan, A., \u0026amp; Rich, J. D. (2020). Treating opioid use disorder and related infectious diseases in the criminal justice system. \u003cem\u003eInfectious Disease Clinics of North America\u003c/em\u003e, \u003cem\u003e34\u003c/em\u003e(3), 585\u0026ndash;603. https://doi.org/10.1016/j.idc.2020.06.012\u003c/li\u003e\n\u003cli\u003eFadnes, L. T., Aas, C. F., Vold, J. H., Leiva, R. A., Ohldieck, C., Chalabianloo, F., Skurtveit, S., Lygren, O. J., Dalg\u0026aring;rd, O., Vickerman, P., Midgard, H., L\u0026oslash;berg, E.-M., Johansson, K. A., \u0026amp; for the INTRO-HCV Study Group. (2021). Integrated treatment of hepatitis C virus infection among people who inject drugs: A multicenter randomized controlled trial (Intro-hcv). \u003cem\u003ePLOS Medicine\u003c/em\u003e, \u003cem\u003e18\u003c/em\u003e(6), e1003653. https://doi.org/10.1371/journal.pmed.1003653 \u003c/li\u003e\n\u003cli\u003eZiff, J., Vu, T., Dvir, D., Riazi, F., Toribio, W., Oster, S., Sigel, K., \u0026amp; Weiss, J. (2021). Predictors of hepatitis C treatment outcomes in a harm reduction-focused primary care program in New York City. \u003cem\u003eHarm Reduction Journal\u003c/em\u003e, \u003cem\u003e18\u003c/em\u003e(1), 38. https://doi.org/10.1186/s12954-021-00486-4\u003c/li\u003e\n\u003cli\u003eGuti\u0026eacute;rrez-Rojas, L., De La G\u0026aacute;ndara Mart\u0026iacute;n, J. J., Garc\u0026iacute;a Buey, L., Uriz Otano, J. I., Mena, \u0026Aacute;., \u0026amp; Roncero, C. (2023). Patients with severe mental illness and hepatitis C virus infection benefit from new pangenotypic direct-acting antivirals: Results of a literature review. \u003cem\u003eGastroenterolog\u0026iacute;a y Hepatolog\u0026iacute;a (English Edition)\u003c/em\u003e, \u003cem\u003e46\u003c/em\u003e(5), 382\u0026ndash;396. https://doi.org/10.1016/j.gastre.2022.06.009\u003c/li\u003e\n\u003cli\u003eAdler, A. J., Drown, L., Boudreaux, C., Coates, M., Marx, A., Akala, O., Waqanivalu, T., Xu, H., \u0026amp; Bukhman, G. (2023). Understanding integrated service delivery: A scoping review of models for noncommunicable disease and mental health interventions in low-and-middle income countries. \u003cem\u003eBMC Health Services Research\u003c/em\u003e, \u003cem\u003e23\u003c/em\u003e(1), 99. https://doi.org/10.1186/s12913-023-09072-9\u003c/li\u003e\n\u003c/ol\u003e"},{"header":"Tables","content":"\u003cp\u003e\u003cstrong\u003eTable 1\u003c/strong\u003e: Summary of selected studies demonstrating the interaction between mental health disorders and hepatitis C virus infection among people who use drugs. SMI = Serious Mental Illness; SUD = substance use disorder; PWUD = People Who Use Drugs; HCV = Hepatitis C Virus.\u003c/p\u003e\n\u003ctable border=\"1\" cellspacing=\"0\" cellpadding=\"0\"\u003e\n \u003ctbody\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 113px;\"\u003e\n \u003cp\u003e\u003cstrong\u003eAuthor(s) (Year)\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 134px;\"\u003e\n \u003cp\u003e\u003cstrong\u003eStudy Design\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 123px;\"\u003e\n \u003cp\u003e\u003cstrong\u003ePopulation Focus\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 254px;\"\u003e\n \u003cp\u003e\u003cstrong\u003eKey Findings Relevant to HCV \u0026amp; Mental Health\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 113px;\"\u003e\n \u003cp\u003e\u003cstrong\u003eBraude et al. (2021)\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 134px;\"\u003e\n \u003cp\u003eSystematic Review \u0026amp; Meta-analysis\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 123px;\"\u003e\n \u003cp\u003eIndividuals with Serious Mental Illness (SMI)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 254px;\"\u003e\n \u003cp\u003eIn SMI communities, the prevalence of HCV is approximately 8%, which is up to 11 times greater than in the general population.\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 113px;\"\u003e\n \u003cp\u003e\u003cstrong\u003eConnery et al. (2020)\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 134px;\"\u003e\n \u003cp\u003eEpidemiological Overview\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 123px;\"\u003e\n \u003cp\u003eGlobal populations with substance use disorders (SUD)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 254px;\"\u003e\n \u003cp\u003eApproximately 40% of drug users fit the criteria for a co-occurring mental health condition.\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 113px;\"\u003e\n \u003cp\u003e\u003cstrong\u003eRoncero et al. (2023)\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 134px;\"\u003e\n \u003cp\u003eCross-sectional Study\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 123px;\"\u003e\n \u003cp\u003ePatients with chronic mental disorders\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 254px;\"\u003e\n \u003cp\u003eDue to increased rates of risky behaviors (such as sharing syringes), dual illnesses (mental illness + substance use) dramatically raise the risk of HCV.\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 113px;\"\u003e\n \u003cp\u003e\u003cstrong\u003eGupta et al. (2022)\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 134px;\"\u003e\n \u003cp\u003eCohort Study\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 123px;\"\u003e\n \u003cp\u003eYoung PWID in rural New Mexico\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 254px;\"\u003e\n \u003cp\u003eReceptive syringe sharing (RSS) is one of the dangerous injection practices that mediates the considerable influence of PTSD on HCV infection rates.\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 113px;\"\u003e\n \u003cp\u003e\u003cstrong\u003eGuo et al. (2023)\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 134px;\"\u003e\n \u003cp\u003eMechanistic Review\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 123px;\"\u003e\n \u003cp\u003ePatients with HCV and depression\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 254px;\"\u003e\n \u003cp\u003eNeuroinflammation linked to chronic HCV plays a role in the pathophysiology of anxiety and depression symptoms.\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 113px;\"\u003e\n \u003cp\u003e\u003cstrong\u003eAhmed et al. (2023)\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 134px;\"\u003e\n \u003cp\u003eReview\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 123px;\"\u003e\n \u003cp\u003eIndividuals with chronic illness \u0026amp; mental health conditions\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 254px;\"\u003e\n \u003cp\u003eThe stigma associated with HCV exacerbates mental illnesses and impedes care engagement by causing social isolation and despondency.\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 113px;\"\u003e\n \u003cp\u003e\u003cstrong\u003eFadnes et al. (2021) (INTRO-HCV)\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 134px;\"\u003e\n \u003cp\u003eRandomized Controlled Trial\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 123px;\"\u003e\n \u003cp\u003ePeople who inject drugs (PWID)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 254px;\"\u003e\n \u003cp\u003eCompared to 77% in normal care, integrated HCV treatment, which combines medical, mental health, and SUD support, achieved 98% treatment initiation.\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 113px;\"\u003e\n \u003cp\u003e\u003cstrong\u003eMahoney et al. (2024)\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 134px;\"\u003e\n \u003cp\u003eNarrative Review\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 123px;\"\u003e\n \u003cp\u003ePWUD in integrated care settings\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 254px;\"\u003e\n \u003cp\u003eMental health outcomes, sustained virologic response (SVR) rates, and drug adherence are all enhanced by integrated care models.\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 113px;\"\u003e\n \u003cp\u003e\u003cstrong\u003eZiff et al. (2021)\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 134px;\"\u003e\n \u003cp\u003eObservational Study\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 123px;\"\u003e\n \u003cp\u003ePWUD in a harm reduction primary care program\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 254px;\"\u003e\n \u003cp\u003eThe completion and follow-up of HCV therapy are significantly predicted by social variables, such as housing instability and insurance type.\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 113px;\"\u003e\n \u003cp\u003e\u003cstrong\u003eAas et al. (2024)\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 134px;\"\u003e\n \u003cp\u003eIntervention Study\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 123px;\"\u003e\n \u003cp\u003ePeople with substance use disorders\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 254px;\"\u003e\n \u003cp\u003eBy lowering psychological discomfort, integrated HCV treatment may lessen the likelihood of HCV transmission.\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 113px;\"\u003e\n \u003cp\u003e\u003cstrong\u003eGuti\u0026eacute;rrez-Rojas et al. (2023)\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 134px;\"\u003e\n \u003cp\u003eLiterature Review\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 123px;\"\u003e\n \u003cp\u003ePatients with severe mental illness \u0026amp; HCV\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 254px;\"\u003e\n \u003cp\u003eIn this co-infected group, new pangenotypic direct-acting antivirals enhance treatment compliance and results.\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 113px;\"\u003e\n \u003cp\u003e\u003cstrong\u003eHashim et al. (2021)\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 134px;\"\u003e\n \u003cp\u003eMeta-analysis\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 123px;\"\u003e\n \u003cp\u003eHomeless PWUD\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 254px;\"\u003e\n \u003cp\u003eThis brings attention to the significant prevalence of HCV and poor mental health, highlighting the necessity of coordinated community-based interventions.\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003c/tbody\u003e\n\u003c/table\u003e\n\u003cp\u003e\u003cstrong\u003eTable 2.\u003c/strong\u003e Selected studies demonstrating the interaction between mental health disorders and hepatitis C virus infection among people who use drugs. SMI = Serious Mental Illness; SUD = substance use disorder; PWUD = People Who Use Drugs; HCV = Hepatitis C Virus.\u003c/p\u003e\n\u003ctable border=\"1\" cellspacing=\"3\" cellpadding=\"0\"\u003e\n \u003cthead\u003e\n \u003ctr\u003e\n \u003ctd\u003e\n \u003cp\u003e\u003cstrong\u003eAuthor(s)\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd\u003e\n \u003cp\u003e\u003cstrong\u003eYear\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd\u003e\n \u003cp\u003e\u003cstrong\u003eStudy Type\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd\u003e\n \u003cp\u003e\u003cstrong\u003ePopulation\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd\u003e\n \u003cp\u003e\u003cstrong\u003eKey Findings\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003c/thead\u003e\n \u003ctbody\u003e\n \u003ctr\u003e\n \u003ctd\u003e\n \u003cp\u003eBraude et al.\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd\u003e\n \u003cp\u003e2021\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd\u003e\n \u003cp\u003eSystematic Review\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd\u003e\n \u003cp\u003eIndividuals with SMI\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd\u003e\n \u003cp\u003eHCV prevalence 3\u0026ndash;11x higher in SMI populations\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd\u003e\n \u003cp\u003eConnery et al.\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd\u003e\n \u003cp\u003e2020\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd\u003e\n \u003cp\u003eEpidemiological Overview\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd\u003e\n \u003cp\u003eGlobal populations with SUD\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd\u003e\n \u003cp\u003e40% of drug users have mental health disorders\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd\u003e\n \u003cp\u003eMahoney et al.\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd\u003e\n \u003cp\u003e2024\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd\u003e\n \u003cp\u003eNarrative Review\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd\u003e\n \u003cp\u003ePWUD in integrated care\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd\u003e\n \u003cp\u003eIntegrated care improves adherence and treatment outcomes\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd\u003e\n \u003cp\u003eHashim et al.\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd\u003e\n \u003cp\u003e2021\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd\u003e\n \u003cp\u003eMeta-analysis\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd\u003e\n \u003cp\u003eHomeless PWUD\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd\u003e\n \u003cp\u003eHigh HCV burden, poor mental health, need for community-based interventions\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd\u003e\n \u003cp\u003eGuo et al.\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd\u003e\n \u003cp\u003e2023\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd\u003e\n \u003cp\u003eMechanistic Review\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd\u003e\n \u003cp\u003ePatients with HCV and depression\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd\u003e\n \u003cp\u003eNeuroinflammation linked to mental health symptoms in chronic HCV\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003c/tbody\u003e\n\u003c/table\u003e"}],"fulltextSource":"","fullText":"","funders":[],"hasAdminPriorityOnWorkflow":false,"hasManuscriptDocX":true,"hasOptedInToPreprint":true,"hasPassedJournalQc":"","hasAnyPriority":false,"hideJournal":true,"highlight":"","institution":"","isAcceptedByJournal":false,"isAuthorSuppliedPdf":false,"isDeskRejected":"","isHiddenFromSearch":false,"isInQc":false,"isInWorkflow":false,"isPdf":false,"isPdfUpToDate":true,"isWithdrawnOrRetracted":false,"journal":{"display":true,"email":"[email protected]","identity":"researchsquare","isNatureJournal":false,"hasQc":true,"allowDirectSubmit":true,"externalIdentity":"","sideBox":"","snPcode":"","submissionUrl":"/submission","title":"Research Square","twitterHandle":"researchsquare","acdcEnabled":true,"dfaEnabled":false,"editorialSystem":"","reportingPortfolio":"","inReviewEnabled":false,"inReviewRevisionsEnabled":true},"keywords":"Hepatitis C, mental health disorders, drug use, co-occurring disorders, integrated care, public health","lastPublishedDoi":"10.21203/rs.3.rs-8702097/v1","lastPublishedDoiUrl":"https://doi.org/10.21203/rs.3.rs-8702097/v1","license":{"name":"CC BY 4.0","url":"https://creativecommons.org/licenses/by/4.0/"},"manuscriptAbstract":"\u003ch2\u003eBackground\u003c/h2\u003e \u003cp\u003ePeople Who Use Drugs (PWUD) are disproportionately affected by both Mental Health Disorders (MHD) and Hepatitis C Virus (HCV). Research indicates that individuals with Serious Mental Illness (SMI) have an HCV prevalence of approximately 8%, while nearly 40% of drug users report conditions such as depression, anxiety, and bipolar disorder. There is a dearth of knowledge on the intersection of HCV, MHD, and substance abuse.\u003c/p\u003e\u003ch2\u003eMethods\u003c/h2\u003e \u003cp\u003eThis narrative literature review synthesizes findings from peer-reviewed research examining the bidirectional relationship between mental health disorders and HCV among PWUD. Studies were identified using targeted keyword searches across multiple databases, focusing on co-occurrence, prevalence, treatment outcomes, and risk factors.\u003c/p\u003e\u003ch2\u003eResults\u003c/h2\u003e \u003cp\u003eMental health conditions contribute to increased HCV risk by promoting risky behaviors such as needle sharing and reduced adherence to HCV treatment. Conversely, HCV negatively affects mental health via biological mechanisms like neuroinflammation and the psychological burden of chronic illness. Integrated treatment models addressing both mental health and HCV show improved adherence and outcomes, though evidence remains limited.\u003c/p\u003e\u003ch2\u003eConclusions\u003c/h2\u003e \u003cp\u003eThere is an urgent need for integrated, interdisciplinary approaches to treatment that address both mental health disorders and HCV among drug users. Future research should prioritize longitudinal studies, focus on underrepresented populations, and evaluate the effectiveness of integrated care models.\u003c/p\u003e","manuscriptTitle":"The Bidirectional Relationship Between Mental Health Disorders and Hepatitis C Virus (Hcv) Among Drug Users","msid":"","msnumber":"","nonDraftVersions":[{"code":1,"date":"2026-03-04 13:57:50","doi":"10.21203/rs.3.rs-8702097/v1","editorialEvents":[{"type":"communityComments","content":0}],"status":"published","journal":{"display":true,"email":"[email protected]","identity":"researchsquare","isNatureJournal":false,"hasQc":true,"allowDirectSubmit":true,"externalIdentity":"","sideBox":"","snPcode":"","submissionUrl":"/submission","title":"Research Square","twitterHandle":"researchsquare","acdcEnabled":true,"dfaEnabled":false,"editorialSystem":"","reportingPortfolio":"","inReviewEnabled":false,"inReviewRevisionsEnabled":true}}],"origin":"","ownerIdentity":"68ead0fd-9569-4504-8933-5c99c37d4192","owner":[],"postedDate":"March 4th, 2026","published":true,"recentEditorialEvents":[],"rejectedJournal":[],"revision":"","amendment":"","status":"posted","subjectAreas":[],"tags":[],"updatedAt":"2026-05-04T02:54:41+00:00","versionOfRecord":[],"versionCreatedAt":"2026-03-04 13:57:50","video":"","vorDoi":"","vorDoiUrl":"","workflowStages":[]},"version":"v1","identity":"rs-8702097","journalConfig":"researchsquare"},"__N_SSP":true},"page":"/article/[identity]/[[...version]]","query":{"redirect":"/article/rs-8702097","identity":"rs-8702097","version":["v1"]},"buildId":"XKTyCvWXoU3ODBz1xrDgd","isFallback":false,"isExperimentalCompile":false,"dynamicIds":[84888],"gssp":true,"scriptLoader":[]}